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SUMMARY 
Glioblastoma multiforme (GBM) is the most common malignant central nervous 
system tumor. The ability of glioma cells to rapidly disperse and invade healthy brain 
tissue, coupled with their high resistance to chemotherapy and radiation have resulted in 
extremely poor prognoses among patients. In recent years, nitric oxide (NO) has been 
discovered to play a ubiquitous of role in human physiology and studies have shown that, 
at sufficient concentrations, NO is able to induce apoptosis as well as chemosensitization 
in tumor cells. In this thesis the synthesis and characterization of targeted NO donors for 
the treatment of GBM is discussed. 
Two glioma targeting biomolecules, Chlorotoxin (CTX) and 
VTWTPQAWFQWVGGGSKKKKK (VTW) were reacted with NO gas to synthesize 
NO donors. These NO donors, CTX-NO and VTW-NO, released NO for over 3 days and 
were able to induce cytotoxicity in a dose dependent manner in glioma cells. The biggest 
advantage, a result of the targeted delivery of NO, was that the NO donors did not have 
toxic effects on astrocytes and endothelial cells. To characterize the chemosensitizing 
effects of CTX-NO, cells were incubated with CTX-NO prior to exposure to 
temozolomide (TMZ) or carmustine (BCNU). These drugs are the most popular 
chemotherapeutics used in the treatment of GBM, but have only shown modest 
improvements in patient survival. Viability studies showed that CTX-NO selectively 
elicited chemosensitivity in glioma cells, whereas the chemosensitivty of astrocytes and 
endothelial cells remained unaffected.  Further investigation showed that CTX-NO 
pretreatment decreased O6-methylguanine DNA methyltransferase (MGMT) and p53 
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levels, suggesting that a decrease in DNA repair ability may be the mechanism by which 
chemosensitivity is induced.   
Lastly, the effects of CTX-NO on glioma cell invasion and migration were 
studied using Boyden chamber and modified scratch assays. Non-toxic doses of CTX-NO 
decreased glioma cell invasion in a dose dependent manner. Studies quantifying matrix 
metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) surface 
expression demonstrated that while MMP-2 expression was decreased by both CTX and 
CTX-NO, MMP-9 expression was decreased only by CTX-NO. Furthermore quantifying 
MMP-2 and MMP-9 activity levels showed that NO and CTX work synergistically to 
decrease the activity of the enzymes. These studies demonstrate that the decrease in 
glioma invasion resulting from CTX-NO treatment was partially a consequence of 
decreased levels of surface and activated MMP-2 and MMP-9. The work presented in this 
thesis describes a novel approach to treating GBM that can be modified to develop 
treatments for various other tumors. Furthermore this is the first study to develop glioma-




CHAPTER 1: INTRODUCTION 
 
In this thesis, the development of novel, targeted nitric oxide donors for the 
treatment of glioblastoma multiforme, a Grade IV brain tumor, is discussed. The 
American Cancer Society estimates that 22,910 brain and spinal cord tumors will be 
diagnosed in the United States during 2012 [1].  Furthermore, they also estimate that in 
2012, brain and spinal cord tumors will cause 2.4% of all deaths caused by cancer [1]. 
Glioblastoma multiforme is the most common central nervous system (CNS) tumor, 
accounting for over 50% of all CNS neoplasms in the United States [2-4]. It is also is the 
most aggressive brain cancer in adults [5].  Patients diagnosed with the disease have a 
median survival of only 14.6 months and the 5-year survival is less than 5% despite 
aggressive multimodal therapy [6-8]. The invasive nature of glioma cells allows the 
tumor to rapidly invade healthy brain tissue [8, 9]. This, coupled with their high 
resistance to chemotherapy and radiotherapy, has significantly hampered the success of 
various treatment options.  
 
1.1 Classification of Brain Tumors 
Brain tumors originating from glial cells, the supporting cells in the brain, are 
categorized as gliomas. There are three types of glial cells: astrocytes, oligodendrocytes, 
and ependymal cells [10]. Astrocytomas, which are gliomas developed from astrocytes, 
account for 80-85% of all gliomas [8]. The World Health Organization has classified 
astrocytomas into four grades according to histopathology. Grade I astrocytomas usually 
lack atypia, mitoses, endothelial proliferation, and necrosis, while Grade II only have 
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atypia [11]. Since these are the characteristics that reflect the malignant potential of the 
tumor, patients with Grade I or II actrocytomas, classified as low grade astrocytomas, 
have much better prognoses. Malignant astrocytomas are Grade III, anaplastic 
astrocytoma, and Grade IV, glioblastoma multiforme (GBM) [12].  
 
1.2 Glioblastoma Multiforme 
GBM is characterized by the presence of necrotic areas in the brain tissue 
surrounded by anaplastic and poorly differentiated cells and hyperplastic blood vessels 
[13]. Other histopathalogical features of the tumor include cellular polymorphism and 
brisk mitotic activity, resulting in tumor heterogeneity [14]. A defining feature of GBM 
tumors is rapid and highly invasive growth [9]. Among the most common symptoms in 
GBM patients are progressive headaches, along with vasogenic edema, a consequence of 
the rapidly growing nature of the tumor [15]. Other symptoms include vomiting and 
clouding of consciousness [16]. As the disease progresses, patients suffer from loss of 
neurological function [15]. The most devastating of GBM symptoms is cognitive 
dysfunction, with patients occasionally undergoing psychiatric evaluation because of 
changes in behavior and personality [15]. 
The invasive nature of GBM cells prevents complete tumor resection, as 
malignant glioma cells are able to spread and invade the brain parenchyma [17, 18]. This 
results in GBM reoccurrence within a median time of 7 months [6, 19]. Secondary GBM 
tumors, or lesions, usually occur within 2-3 cm from the border of the original tumor site, 
and are resistant to radiation and chemotherapy [12, 14, 20]. Secondary GBM lesions are 
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often irregularly shaped and include cystic areas, further complicating tumor resection 
[21]. There is no standard of care for recurrent GBM and treatment is case specific [22].  
 
1.2.1 Glioma Invasion  
The molecular mechanisms of glioma invasion are complex and not completely 
elucidated, but there is consensus that a critical step in tumor invasion is the degradation 
of the extracellular matrix (ECM) and penetration into adjacent brain structures [23-25]. 
Matrix metalloproteinases (MMPs) are a group of zinc dependent endopeptidases that 
play a key role in the degradation of the ECM [26-28]. There are over 20 different 
MMPs, all of which are expressed as inactive pro-enzymes, and activation requires 
proteolytic cleavage [29, 30]. MMPs are divided, based on their substrate specificities, 
into six major groups: collagenases, gelatinases, stromelysins, matrilysin, membrane-type 
matrix metalloproteinases (MT-MMPs), and others [29, 31]. MMP-1, MMP-8 and MMP-
13 cleave triple helical collagen and are hence classified as collagenases [25]. MMP-2 
and MMP-9, the gelatinases, degrade denatured collagen IV, while stromelysins and 
matrilysins degrade aggrecan, fibronectin, laminin and other molecules [25]. The MT-
MMP subgroup differs from the other MMPs in that they are anchored to the plasma 
membrane [28]. MMP activity is controlled by gene transcription, zymogen activation by 
proteolysis, and inhibition by tissue inhibitors of metalloproteinases (TIMPs) [24].  In 
addition to MMPs, a variety of other chemokines, integrins and cell adhesion molecules 
play critical roles in modulating tumor cell invasion, and it is the cumulative effect of 




1.3 Glioblastoma Multiforme Treatment Options 
Treatment of GBM is particularly challenging because of various reasons, which 
include localization in the brain, intrinsic resistance to chemotherapy, limited ability of 
the brain to repair itself, and the neurotoxicity of anti-tumor drugs [32]. Surgery, the 
earliest treatment option for GBM patients, remains the first step in patient care [16, 33-
35]. Although significant improvements in surgical and imaging techniques have been 
made since the first reported GBM resection in 1904, the diffuse nature of these types of 
tumors makes complete tumor resection impossible [35-38]. Nonetheless, maximal tumor 
resection has been shown to enhance the efficacy of subsequent chemotherapy [35].  
The first major advance in GBM treatment occurred in 1978 when Walker et al. 
showed that external beam radiation was able to increase median patient survival from 14 
weeks to 35 weeks [39]. Between 1978 and 2003, no significant improvement in the 
prognoses of GBM patients was achieved, and overall patient survival remained in the 
range of 10-12 months [3, 12]. The current standard of care for GBM is multimodal 
treatment, involving surgical tumor resection followed by radiation and chemotherapy 
[51, 56, 57]. Figure 1.1 shows MRI scans of a patient who, despite undergoing surgical 
resection, radiation and chemotherapy, died 17 months after surgery [8]. Although 
numerous chemotherapeutics have been used to treat GBM in the last decade, two new 
therapies, Gliadel® wafers and temozolomide (TMZ), have been FDA approved for the 
treatment of GBM and have been incorporated into the standard GBM treatment regimen 





Figure 1.1. Local recurrence of glioblastoma. A right occipital glioblastoma (left) was operated 
upon, and a postoperative magnetic resonance imaging (MRI) scan confirmed complete removal 
(middle left). Chemotherapy and sixty-Gy radiation therapy were administered. Twelve months 
later, a routine MRI showed a recurrent tumor immediately adjacent to the resection cavity 




In 2003, carmustine (BCNU)-loaded wafers, Gliadel®, were FDA approved as 
adjuncts to surgery for first-line treatment of GBM [41]. BCNU, 1,3-Bis(2-chloroethyl)-
1-nitrosourea, is a chemotherapeutic with alkylating and carbomylating effects that has 
been used for GBM treatment for more than 30 years [42]. Prior to the approval of 
Gliadel®, BCNU was administered intravenously [42]. In aqueous solution, BCNU 
decomposes to 2-chloroethyl diazohydroxide and 2-chloroethyl isocynate [43]. 2-
chloroethyl diazohydroxide primarily has alkylating effects and inhibits DNA synthesis 
by adding alkyl groups to the O6 position of guanine (O6-G). Conversely, 2-chloroethyl 
isocynate has carbomylating effects, whereby enzymes involved in maintaining cellular 
redox homeostatis are inactivated, resulting in the accumulation of oxidized gluthatione 
and consequent tumor cell death [44]. 
BCNU has a small molecular weight, is highly lipophilic, and is able to cross the 
blood brain barrier rapidly [45].  Additionally, it is rapidly metabolized in brain fluid as 
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well as plasma, and has high urine clearance (60-70% of the dose is eliminated in urine) 
[46]. Thus, for therapeutic purposes high doses were necessary, resulting in severe side 
effects. Gliadel® wafers prevent the side effects associated with high systemic doses by 
providing continuous, intracranial delivery (Fig. 1.2) [47]. However, the wafer implant 
has been associated with cerebral edema, healing abnormalities, intracranial infections, 
seizures, and cyst formation [47, 48]. Furthermore, one-third of patients do not respond to 
BCNU treatment [49].    
 
Figure 1.2. After glioma resection, eight Gliadel wafers were placed in the tumor cavity. Loading 
BCNU into the degradable polymer wafers allows controlled, localized delivery of the drug [50]. 
 
Temozolomide 
In 2005, a new chemotherapeutic agent, TMZ, which had shown a modest 
increase in patient survival when administered with and after radiation (2 year survival 
26% vs. 10%), was FDA approved for the treatment of GBM [41, 51]. TMZ is a second-
generation imidazotetrazine prodrug, which acts as a methylating agent [2, 52, 53]. TMZ 
hydrolyzes at physiological pH into its active product, 5-(3-methyltriazen-1-yl)imidazole-
4-carboxamide (MTIC) [53]. MTIC is able to methylate DNA at a variety of nucleophilic 
centers, including O6-G, forming O6-methylguanine [54]. O6-methylguanine mispairs 
with thymine, and the failure of DNA mismatch repairs result in tumor cell death [54, 
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55]. TMZ has quickly been incorporated into the treatment regimen of GBM patients 
because it is taken orally, and has 100% bioavailability [53]. Furthermore, TMZ is able to 
cross the blood brain barrier, and over 30% of the drug enters the cerebrospinal fluid, 
which is a major reason for its efficacy [55].  
 
Second line treatment options: Bevacizumab and the NovoTTF-100A System 
For GBM patients who do not respond to surgery and radiation combined with 
TMZ or BCNU, two new therapeutic options, Bevacizumab and the NovoTTF-100A 
System, have recently received FDA approval as second-line treatment options. 
Bevacizumab (Avastin®) injection received FDA approval in May 2009 [41]. 
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that selectively 
binds to vascular endothelial growth factor (VEGF) and subsequently neutralizes its 
activity [41]. Although Bevacizumab does not inhibit the growth of solid tumors, it is 
able to normalize tumor vasculature to a certain degree, reducing the incidence of tumor 
related edema [41].  
The most recent treatment regiment to receive FDA approval for second-line 
glioma treatment is the NovoTTF-100A System, which was approved in April 2011 [58, 
59]. The NovoTTF system emits an electromagnetic field that interferes with cell 
division, causing disruption of chromosome segregation, blebbing of the cytoplasmic 
membrane, and eventually, cell death [59].  This system, which is in clinical trials, has 
been shown to have equivalent efficacy to cytotoxic chemotherapies, but fewer side 




1.4 Experimental and Novel treatments 
 The poor prognoses of GBM patients, in spite of the administration of the best 
available therapy, has resulted in a variety of studies for the development of novel GBM 
therapies, some of which are discussed herein. Ascorbate, or vitamin C, is an essential 
micronutrient that has been shown to inhibit GBM growth and induce radiosenitivity in 
tumor cells; however, maintaining therapeutic plasma levels has been the main hindrance 
in the success of ascorbate as a GBM treatment  [5, 61]. Curcumin is another biomolecule 
that is widely investigated as a potential GBM therapeutic because of its apoptosis-
inducing and chemosensitization effects on glioma cells [62-64]. The main challenges in 
the use of curcumin are water insolubility, low bioavailability, and high rate of 
metabolism [65]. 
In addition to the use of naturally occurring molecules, gene therapy is another 
alternative for GBM treatment that is currently being researched. Gene therapy for GBM 
involves the delivery of suicide genes [66, 67], pro-apoptotic genes [68-71] or genes 
inhibiting invasion [72]. Some success has been achieved in preclinical trials of various 
gene therapies, but the main challenges in clinical trials have been the delivery of the 
genes specifically to tumor cells and minimizing the bystander effect to surrounding 
healthy tissues [73] 
An indirect approach to treating GBM has been the development of anti-
angiogenic therapy. Angiogenesis is a vital process for the growth of all tumors, and 
inhibiting this process decreases blood supply to the tumor, depriving tumor cells of vital 
nutrients and oxygen [74]. Numerous anti-angiogenic agents, such as cediranib [75], 
sorafenib [76], cilengitide [77], pazopanib [78] and sunitinib [79] have been developed 
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and are currently undergoing clinical trials. A major concern in anti-angiogenic therapy is 
the increased risk of intracranial hemorrhaging; however, the success of bevaciumab, an 
anti-angiogenic agent, in clinical trials and its consequent FDA approval has helped in 
affirming the safety of this approach to GBM treatment [6, 80]. Although various drugs 
have been developed, a major reason for the lack of GBM patient response to 
chemotherapy is the use of systemic delivery of chemotherapeutic drugs. The inability of 
chemotherapeutics to accumulate within the tumor because of hindrances caused by the 
blood brain barrier (BBB) and the blood brain tumor barrier (BTB) contributes 
significantly to the failure of a variety of drugs in treating GBM [81, 82].  
 
1.5 The Blood Brain Barrier: Obstacle for drug delivery  
The BBB is composed of endothelial cells supported by tight junctions. These 
junctions maintain the brain homeostasis by controlling the exchange of soluble factors 
between the endothelial cells and the cerebrospinal fluid [83]. The BBB plays an essential 
role in preventing bacteria from reaching the brain. As a result, only small, lipophilic 
compounds that have a molecular mass of less than 400-500 Daltons are able to passively 
cross the BBB [84]. However, certain endogenous large molecules (e.g. insulin and 
transferrin) are able to cross the BBB via receptor-mediated transcytosis [85].  
In patients with gliomas, a secondary barrier, the BTB, also develops. The BTB, 
which includes the microvessels supplying brain tumors, retains many characteristics of 
the normal BBB and restricts the paracellular diffusion of hydrophilic molecules [86, 87]. 
However, some transmembrane tight junction components are down-regulated in 
glioblastomas, resulting in the BTB having a higher permeability than the BBB [81, 88]. 
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Despite this, the BTB still is a significant barrier, restricting the penetration of 
therapeutics into the glioma [86].  Furthermore, the permeability of the BBB is disrupted 
only in close proximity to the tumor, and thus delivering drugs to single cells in the 
infiltration zone still remains a challenge [81, 89]. In order to address this challenge a 
variety of drug delivery techniques have been developed, some of which are discussed in 
the subsequent section.  
 
1.6 Novel drug delivery techniques for GBM treatment  
1.6.1 Intracerebral delivery 
Intracerebral delivery of therapeutics, in comparison to systemic delivery, 
minimizes systemic drug levels, prolongs drug elevation at the tumor site, and limits side 
effects of chemotherapeutic agents [90]. Additionally, in contrast to non-CNS tumors, 
GBM rarely spreads systemically, making intracerebral delivery of chemotherapeutics for 
GBM extremely suitable [42]. Intracerebral delivery can be administered by convection 
enhanced delivery (CED) techniques, biodegradable drug delivery carriers, subcutaneous 
reservoirs, or manual injection [91]. A number of clinical studies have used intratumoral 
delivery of various chemotherapeutics, including BCNU [90, 92], TMZ [93],  bleomycin 
[94], doxorubicin [95, 96], carboplatin [97, 98], and cisplatin [99], and found it to be a 
safe and effective method of delivery.  
 
1.6.2 Nanoparticles 
A number of researchers have developed passive tumor-targeting nanoparticles 
and micelles by exploiting the enhanced permeability and retention (EPR) effect [100-
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102]. The EPR effect describes the accumulation of drug/nanoparticles at the tumor site 
due to high vascular density coupled with the defective architecture of vascular 
endothelium within a tumor [103]. Furthermore, the lack of lymphatic drainage within a 
tumor contributes to the retention of nanoparticles, increasing their accumulation at the 
tumor site [103-105]. An added advantage of nanoparticles is that by encapsulating the 
drug within the nanoparticle, plasma levels of the free drug are decreased, ameliorating 
the toxic effects to healthy tissue [34].  
 Solid Lipid Nanoparticles (SLNs) are the best characterized nontoxic 
nanoparticles used for the treatment of brain tumors [102]. Drug loaded SLNs have been 
shown to have higher physical stability, tolerability, greater protection from degradation, 
and better release profiles of incorporated drugs in comparison to other vehicles [106-
109]. Magnetic nanoparticles are also widely studied as potential GBM therapeutics, 
particularly because of their multifunctionality as magnetic resonance imaging (MRI) 
contrast agents as well as drug carriers [22, 110-113].  
 
 1.6.3 Targeted drug delivery 
GBM tumor masses are often composed of 109 to 1012 competent cells, often 
extending beyond the tumor margins, and the doses required to treat a tumor of this size 
are severely toxic to healthy tissue [82]. Despite the success of the passive targeting 
mechanism resulting from the EPR effect, it has been shown that a more active form of 
targeting, such as ligand-mediated targeting, proves to be more effective in tumor cell 
recognition and internalization of drugs via endocytosis [114, 115]. Nanoparticles coated 
with ligands for receptors overexpressed in GBM cells, such as endothelial growth factor 
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receptor (EGFR) [111, 116], interleukin-4 receptor [117], MMP-2 [115] and low-density 
lipoprotein receptor-related protein receptor [118], have resulted in increased drug 
accumulation at the tumor site, as well as MRI contrast enhancement in comparison to 
uncoated nanoparticles. Therefore, by efficiently targeting tumor cells via ligand-receptor 
binding, increased bioavailiblity and a reduction in minimum effective dose and systemic 
toxicity can be achieved [100, 119]. Furthermore, targeted drug delivery also limits the 
development of multidrug resistance, which is often the cause of tumor reoccurrence 
[119, 120].   
 Additionally, numerous targeted chemotherapeutics such as inhibitors of EGFR 
[121, 122], VEGF [75], and αvβ3 and αvβ5 integrins [80, 123] have been developed for the 
treatment of glioblastoma. Despite the number of targeted agents that have been 
developed for GBM treatment, most of them have resulted in disappointing clinical 
results, which at best have shown only modest improvement in patient survival [2]. 
Presented herein is the development of an innovative cytotoxic drug that can target 
glioblastoma cells. The objective of this work was the development of nitric oxide (NO) 
donors, which would be delivered intracerebrally, and deliver NO specifically to the 








Figure 1.3. Proposed drug delivery scheme. GBM patient undergoes surgery for tumor resection; 
consequently  the targeted nitric oxide drug is administered intracerebrally. The NO donor is able 
to deliver NO selectively to tumor cells, causing cytotoxic effects. A secondary benefit of NO is 
the enhanced permeability of the blood brain barrier which will result higher concentrations of 
chemotherapeutics at the tumor site. 
 
1.7 Nitric Oxide 
NO is a small, easily diffusible gaseous molecule that has been found to play 
numerous roles in human physiology. NO is soluble in water and lipids and its half-life in 
situ is a few seconds [124]. NO, as a result of its reactive nature, has a relatively small 
sphere of influence, extending approximately 100 µm from its origin [125]. NO acts as a 
signaling molecule in vascular, neurological and cytotoxic functions in the human body. 
Many of these functions, including smooth muscle relaxation, neurotransmission, and the 
inhibition of platelet aggregation, are mediated by the NO-cyclic guanosine 
monophosphate (cGMP) pathway [126]. Another mechanism of NO signaling is by the 
post-translational modification of proteins by the S-nitrosylation of cysteine thiol 
residues, resulting in protein activation or modulation of the protein’s binding capability 
[127]. Alternatively S-nitrosylation can also cause the denaturation of proteins, resulting 
in a loss of catalytic functions [128, 129]. 
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NO has both supportive and adverse effects to tissue function. NO transiently 
produced by inflammatory cells prevents invasion of tissue by microorganisms, whereas 
a sustained response would result in organ failure and septic shock [130]. NO can 
function as an antioxidant by removing the O2
● radical; however, this reaction forms the 
cytotoxic peroxynitrite (ONOO−) [130]. Conversely, by reacting with fatty alkoxyl or 
peroxyl radicals, NO effectively removes them from the system, where they would 
otherwise damage cell membranes [130]. In the presence of water and oxygen, NO can 
react with oxygen to form reactive nitrogen oxide species (RNOS) [131]. Some RNOS 
mimic the activity of NO, whereas others are toxic to the structure or function of proteins, 
lipids, carbohydrates, and nucleic acids [132]. Due to the important and double edged 
role NO plays in the body, its generation is enzymatically controlled  by nitric oxide 
sythases [130]. 
 
Nitric oxide sythases (NOS) 
Nitric oxide sythases (NOS) are a family of enzymes that catalyze the conversion 
of L-arginine to L-citrulline, a reaction that generates NO (Fig. 1.4) [133]. There are three 
isoforms of NOS; neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS 
(eNOS) [134]. eNOS and nNOS are constitutively expressed in neural and endothelial 
cells, and are hence referred to as constitutive NOS (cNOS). The activity of cNOS is 
dependent on cytosolic calcium concentration [135]. Various physiological stimuli can 
increase Ca2+ concentration, facilitating the binding of calmodulin to cNOS. The binding 
of calmodulin activates cNOS, consequently initiating the production of NO from L-
arginine (Fig. 1.4) [136]. iNOS, conversely, is transcriptionally controlled, and its activity 
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is induced by inflammatory cytokines, endotoxins, hypoxia, and oxidative stress (Fig. 
1.2) [137, 138]. The production of NO from iNOS, which may last up to a period of 
hours or even days, is independent of intracellular calcium levels and is much greater 
(micromolar) in comparison to that produced by cNOS (picomolar to nanomolar) [137, 
139]. NO generated from eNOS and nNOS exerts its biological function via the cGMP 







Figure 1.4. Schematic representation of the mechanisms of the different NOS isoforms 
Abbreviations BH4: tetrahydrobiopterin, CaM: calmodulin, COX-2: cyclo-oxygenase 
type 2, γ-IFN: gamma interferon, IL-1: interleukin-1, LPS: lipopolysaccharide, NF-κB: 
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1.7.1 Role of Nitric Oxide in Gliomas 
Nitric oxide plays a ubiquitous role in malignant gliomas. Depending on the 
concentration and duration of exposure of NO to the glioma, it can induce or inhibit 
tumor progression and metastasis [126]. The effect of NO in gliomas is a culmination of: 
(1) the direct effect of NO on glioma cell proliferation and glioma cell invasion, (2) the 
effects of NO on chemotherapy and radiotherapy, (3) the indirect effect of NO on 
inflammatory and immune responses to gliomas, and (4) the vascular effects of NO in 
gliomas [141]. 
 
Effect of NO on glioma cell proliferation  
In terms of cell viability, NO has been shown to have both pro and anti-tumor 
activity. A number of studies have shown that at micromolar concentrations of NO 
released from exogenous donors, glioma growth is inhibited [19, 142-146].  Exposure to 
NO, both directly and indirectly, has cytotoxic effects on glioma cells. NO can directly 
inhibit mitochondrial aconitase, thereby hindering cellular respiration [124]. NO can also 
inhibit the activity of ribonucleotide reductase and iron-responsive binding protein, which 
is essential in the regulation of the transcription of iron responsive elements [124]. 
Moreover, NO inhibits the activity of T4 DNA ligases, which repair DNA strands [131]. 
NO-damaged DNA repair enzymes induce delayed apoptosis, or alternatively, NO can 
increase levels of caspase-8 in glioma cells, triggering caspase-dependent apoptosis 
[146]. NO metabolites, nitrosothiols, nitrosamines, peroxynitrates, and RNOS also play a 
role in regulating the cytotoxic effects of NO, including DNA damage, lipid oxidation, 
protein modification, and alterations in enzyme activity, resulting in apoptosis and 
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necrosis [147, 148]. Thus, NO induces cytotoxicity via a number of different 
mechanisms.  
Alternatively, S-nitrosylation of caspases, a family of cysteine proteases, by NO 
and its metabolites results in apoptosis-resistant cells, which in turn causes further 
accumulation of mutations and subsequent clonal selection [148]. Nitrosamines can be 
potentially carcinogenic and can also cause the deamination of nucleotides, leading to 
mutation and inhibition of DNA synthesis [124]. Studies have shown increased levels of 
cNOS and iNOS mRNA in gliomas in comparison to normal brain tissue [149, 150]. It 
has been reported that tumor-derived endogenous NO, usually in the pico- to nanomolar 
range, can enhance tumor growth [151]. Eyler et al. demonstrated that glioma stem cells 
(GSCs) have elevated iNOS levels and inhibition of iNOS resulted in decreased GSC 
growth and tumorgenicity, suggesting that NO has a cytoprotective role in GSCs [152]. 
Additionally the genetoxic properties of NO described previously can also be used by 
tumor cells to cause damage in surrounding healthy tissues.  In order to explain these 
contradictory effects of NO on gliomas, it has been suggested that whereas endogenous 
NO is generally cytoprotective, the effects of exogenous NO, although dependent on the 
concentration and type of NO releasing compound, are by and large cytotoxic in gliomas.   
 
Effect of NO on glioma cell invasion 
The role of NO in glioma cell invasion, as its role in glioma cell proliferation, is 
ambiguous. The effect of NO on the proteolytic enzymes involved in invasion plays a 
critical role in determining whether invasion is enhanced or inhibited. Pullen et al. 
showed treatment of glioma cells with an NO donor resulted in increased MMP-1 
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secretion and glioma motility [153]. Another study showed increased MMP-2 expression 
in glioma cells after NO treatment [154]. On the other hand, it has been shown that 
treatment with NO releasing compound decreases MMP-9 activity [155, 156]. 
Additionally, NO treatment has been shown to inhibit hypoxia-induced tumor cell 
invasion by down-regulating hypoxia inducible factor-1 (HIF-1) and impairing 
mitochondria function [157]. Thus although there is contradictory evidence as to the 
effects of NO on glioma invasion, it is recognized that NO plays an important role in 
modulating invasion.    
 
NO and GBM chemosensitivity and radiosensitivity  
Similar to the effect of NO on glioma viability and invasion, the effect of NO on 
glioma chemosensitivity and radiosensitivity has been debated.  Kurimoto et al. showed 
that when glioma cells were exposed to radiation in the presence of exogenous NO 
donors at a concentration of 100 µM, radiosensitivity was enhanced up to 1.9 times [143]. 
However, it is not completely understood as to how NO induces radiosensitization. 
Potential mechanisms include direct DNA damage, lipid peroxidation, mitochondrial 
damage, and intracellular reduction of glutathione [143]. Additionally, studies have used 
a variety of NO donors to induce chemosensitivity of glioma cells towards BCNU [158], 
TMZ [146], and carboplatin [19]. It is most likely that a variety of mechanisms, including 
inhibition of DNA synthesis, generation of toxic ROS, and inhibition of DNA repair by 
NO-induced interaction with DNA repair enzymes, result in the enhancement of 
chemosensitivity [146, 159, 160]. Deactivation of proteins involved with 
chemoresistance, for example, the arylation of glutathione (GSH) and the S-nitrosolyation 
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of glutathione-S transferases (GST) by NO and RNOS, has also been shown to contribute 
to the enhancement of chemosensitivity resulting from NO exposure [146]. On the other 
hand, studies have shown that overexpression of iNOS in glioma cells results in 
chemoresistance against the carbomylating action of BCNU [161]. Hence, NO plays a 
complicated role in glioma physiology, and the effects of NO vary greatly depending on 
the concentration as well as the NO releasing compound 
 
Vascular effects of NO in gliomas 
NO plays an important role in the glioma vasculature. One of the roles of NO in 
vasculature is the stimulation of VEGF production, the primary mediator of angiogenesis. 
An overstimulation of VEGF within the tumor tissue results in hyper-vasculature, which 
displays irregular morphology, defective architecture, and enhanced permeability [162]. 
This, coupled with the ability of NO to induce vasodilation via the NO-cGMP pathway, 
suggests that NO is at least partially responsible for the “leaky” vasculature of solid 
tumors [162]. Studies have shown that inhibiting NOS reduces the cerebral blood flow 
(CBF) by approximately 15%, whereas administration of an NO-donor increases the CBF 
by 33% [163]. In another study, oral administration of hydroxyurea and L-arginine 
enhanced levels of NO in the tumor tissue and increased uptake of a radio-labeled tracer 
[87]. Together, these studies suggest that increased levels of NO increase the 
permeability of both the BBB and the BTB. However, the ability to stimulate 
angiogenesis also means that NO can stimulate neovascularization, promoting tumor 





Effect of NO on inflammatory and immune responses to gliomas 
In addition to its role in glioma proliferation, NO plays a significant role in the 
modulation of inflammatory and immune responses to glioma cells. Host cells, including 
macrophages, dendritic cells and natural killer cells, produce NO in response to the 
secretion of interferon gamma (INF-γ) [141]. These cells produce large amounts of NO 
via iNOS and cause glioma cell apoptosis by synergy with cytokines that are part of the 
tumor necrosis factor (TNF) family [124, 139]. In contrast to its effector role in the 
immune system, NO has been shown to have immunosuppressive effects as well. Studies 
have also shown that NO can limit T-cell proliferation and hence limit the antitumor 
response by these cells [166]. Additionally, NO can prevent the adhesion of leukocytes to 
tumor vasculature [166]. Furthermore, Badn et al. showed that the efficacy of 
immunotherapy for gliomas was significantly improved when iNOS activity in glioma 
bearing rats was inhibited [167].  
 
1.8. Nitric Oxide Donors  
The various physiological roles of NO have resulted in its use for the treatment of 
numerous diseases. Since NO gas itself has a short half-life and therefore limited utility 
as a therapeutic agent, a variety of NO donors have been developed [125, 168, 169]. NO 
donors are characterized in the following categories: 1) organic nitrates and nitrite esters, 




The conventionally used cardiovascular drugs nitroglycerin, isosorbide dinitrite, 
and nicorandil are classified as organic nitrates and esters [170]. These drugs release NO 
by metabolism with the help of various enzymes. The major problem in using organic 
nitrates and esters for NO therapy is the development of drug tolerance after long term 
use [170]. The most commonly used NO donor from the second category,  iron nitrosyl 
complexes, is sodium nitroprusside (SNP), which has a complex structure in which a 
nitrosyl group is bound to iron [170].  SNP has been used clinically as a vasodilator but 
its use is limited due to the potential for the induction of thiocynate toxicity as well as an 
increased potential for the formation of the cytotoxic peroxynitrite [140, 170].  
 S-nitrosothiols, the third category of NO donors, are formed by the S-nitrosation 
of thiols. Some S-nitrosothiols occur naturally in vivo, for example, S-nitrocysteine, S-
nitroglutathione, and S-nitrosoalbumin [140]. Some common chemically synthesized S-
nitrothiols are S-nitroso-N-acetylpenicillamine (SNAP) and S-nitrosocaptopril. S-
nitrosothiols can release NO via a number of mechanisms including catalysis by Cu2+ 
ions, reaction with ascorbate, or enzymatic, photochemical or thermal decomposition 
[125, 140]. The fourth category of NO donors, hybrid NO donors, are synthesized by 
adding  an NO-releasing moiety to a drug, to increase its effectiveness [125]. Various 
non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin, ibuprofen and 
diclofenac have been modified to incorporate a NO-releasing molecule [125]. 
 
Diazeniumdiolates 
Diazeniumdiolates, also called NONOates, are a class of NO donors that have a 
diolate group [N(O-)N=O] bound to an amine group [125]. These compounds decompose 
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to release NO in acidic or neutral solutions. Under basic, freeze-dried or frozen states 
diazeniumdiolates are stable. Release rates vary with temperature, pH, and the molecular 
structure of the donor. Increasing the pH of the solution increases the rate of NO release 
[171]. The by-product of the reaction is the original amine compound [172]; this is of 
great importance as many NO donors, such as SNP, produce toxic by-products after 
releasing NO. Diazeniumdiolates, on the other hand, if synthesized from innocuous 
peptides or proteins, can be tailored to release only non-toxic by-products [173].  
Proteins and peptides have a high number of surface amines which, when exposed 
to NO gas, form diazeniumdiolates [174]. The reaction of amines with NO to form 
diazeniumdiolates is an exothermic reaction which can proceed via two different 
mechanisms (Fig. 1.5) [171]. The NO can either react with the amine to form a radical or 
with another NO molecule to form a dimer, which consequently reacts with the amine. 
However, if it is assumed that there is no significant difference in the dissociation of NO 
from either diazeniumdiolate, it is likely that the formation of the radical is the more 
favorable mechanism [171].  
 
 
Figure 1.5. Reaction of free amines with NO gas to form NO-releasing diazeniumdiolates. There 
are two possible ways that the reaction of amines with NO can proceed. The NO can react with 
the amine to form a radical (mechanism 1) or two moles of NO can reaction to form a dimer, 
which then reacts with the amine to form a diazeniumdiolate (mechanism 2). Assuming that there 
are no significant differences in the association of NO from either diazeniumdiolate, it is likely 




In the work discussed in this thesis, the aforementioned reaction of NO with 
amines to form diazeniumdiolate NO donors was utilized. Taylor et al. proposed the 
mechanism of NO release from diazeniumdiolates begins with the protonation of the 
compound to form a thermodynamically unstable moiety (Fig.1.6) [171]. This is followed 
by a second protonation step, in which the protonated NO dimer is released along with 
the original amine compound. Two moles of NO are released after protonation and 




Figure 1.6. The mechanism of NO release from the decomposition of diazeniumdiolates. Release 
of NO is triggered by a protonation step which forms a thermodynamically unstable moiety. In a 
second protonation step the protonated NO dimer is released along with the original amine 
compound. Homolytic cleavage of the NO dimer results is the release of two moles of NO [171]. 
 
1.8.1 Nitric Oxide donors used in GBM treatment 
A variety of exogenous NO donors have been investigated for their anti-glioma 
properties. Kurimoto et al. studied the glioma cell growth inhibition and radiosenitization 
effects of  SNP and SNAP [143]. (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-
nitric oxide (GIT-27NO) is a hybrid NO donor, developed by adding a NO releasing 
moiety to the immunodulatory drug VGX-1027, which has been shown to trigger glioma 
cell death [175]. However, controlled NO release from diazeniumdiolates has made this 
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group of NO donors more popular as potential anti-tumor agents. Weyerbrock et al. 
tested the effect of three diaziumdiolates, proline NONOate (PROLI/NO), diethlyamine 
NONOate (DETA/NO), and spermine NONOate (SPER/NO) and found that both 
DETA/NO and SPER/NO inhibited tumor cell growth at concentrations of 10 mM [19]. 
Additionally O2-[2,4-dinitro-5-(N-methyl-N-4carboxyphenylamino) phenyl] (1-N,N-
dimethylamino)diazen-1-ium-1,2-diolate) (PABA/NO), β-galactosyl-pyrrolidinyl 
diazeniumdiolate (β-Gal-NONOate), and O2-(2,4-Dinitrophenyl) 1-[(4-
ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) have been used to inhibit 
glioma cell growth [145, 146, 176]. Although all of these studies have shown that NO can 
be used to inhibit glioma cell growth, it has been recognized that because of their non-
specific nature these NO donors can result in neurotoxicity.  
Although a dichotomy appears to exist in the various roles NO plays in GBM 
physiology, there is sufficient evidence that exogenous NO donors, in particular 
diazeniumdiolates, are able to inhibit glioma cell growth and increase chemosensitivity. 
However the non-selective nature of previously studied NO donors has the potential to 
cause neurotoxicity. Therefore, in this thesis, the synthesis and characterization of novel 
glioma targeting diazeniumdiolates as well as their effect on glioma cell viability, 




CHAPTER 2: SYNTHESIS AND CHARACTERIZATION OF GLIOMA TARGETING 
NITRIC OXIDE DONORS 
 
2.1 Summary  
GBM is among the most aggressive tumors in the human body, and patient 
survival is often less than one year. Various cytotoxic chemotherapeutic drugs have been 
used to treat GBM, but the efficacy of these drugs is severely limited due to their non-
specific nature, resulting in toxicity towards normal cells. The non-specific nature of 
chemotherapeutics results in most anti-cancer drugs administered at maximum tolerated 
dose, which in turn results in a variety of side effects in the patient. Therefore in order to 
increase patient survival and minimize the toxic side effects of chemotherapy, a number 
of studies have focused on developing effective anti-tumor drugs that are able to target 
tumor cells. Herein, the synthesis and characterization of two novel glioma-targeting NO 
donors is presented. NO is a small yet important biological messenger, which at sufficient 
concentrations has been shown to induce apoptosis as well as increase radiosensitization 
in tumor cells. VTWTPQAWFQWVGGGSKKKKK (VTW) and chlorotoxin (CTX), two 
glioma targeting biomolecules, were transformed into NO donating diazeniumdiolates, 
with half-lives of 24.3 hours and 19.2 hours, respectively. Furthermore, tumor cell 
viability was significantly decreased when cells were incubated with the NO donors 
while the control cell viability was not affected significantly. Fluorescence microscopy 
confirmed that the biomolecules retained their glioma-targeting ability after the 
transformation to NO donors. In addition, confocal microscopy also confirmed the 
endocytosis of both NO donors. The techniques discussed in this chapter can be easily 
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modified to synthesize targeted NO donors from various tumor-targeting peptides and 
proteins to develop disease specific therapeutics.  
 
2.2 Introduction 
The first step in developing glioma specific NO-releasing peptides was the 
identification of GBM targeting peptide sequences. From extensive research, two 
biomolecules that have high affinity for glioma cells were identified. The first, 
chlorotoxin (CTX), is a 36-amino acid protein isolated from the venom of the 
Deathstalker scorpion (Leiurus quinquestriatus) [177, 178]. This protein has four 
disulfide bonds, making the molecule very compact [177]. CTX has a high affinity for a 
lipid raft anchored complex that contains MMP-2 [179-182]. MMP-2 is overexpressed in 
gliomas, but is not expressed in normal glial cells and neurons, allowing highly efficient 
targeting of glioma cells [180, 183-185]. 
CTX has previously been conjugated with supermagnetic nanoprobes, and has 
been used effectively as a diagnostic tool to image gliomas [113, 186]. CTX conjugated 
nanoprobes have shown enhanced targeting specificity as well as benign biological 
response in comparison to current imaging systems that utilize passive targeting to image 
tumors [113, 182, 186, 187]. Furthermore, CTX-labeled nanoparticles have been used for 
targeted green fluorescence protein (GFP) gene delivery, resulting in enhanced GFP 
expression in the glioma cells [188]. In other studies, CTX bound nanoparticles have 
been used to efficiently deliver methotrexate [115], short interfering RNA (siRNA) [113, 
189], and plasmid DNA [190] to glioma cells. These studies showed that not only does 
CTX target glioma, it is also efficiently endocytosed by the cancer cells.  
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The second biomolecule identified was the 12 amino acid peptide sequence 
VTWTPQAWFQWV (VTW-1). This peptide sequence was identified using a 12-mer 
phage display library [191]. Wu et al demonstrated that VTW-1 bound 700-fold more 
effectively to glioma cells in comparison to normal human astrocytes [191]. By 
conjugating a 119 kDa subunit of β-galactocidase, it was also demonstrated that VTW-1 
could be used to deliver proteins into cells [191]. From Basic Local Alignment Search 
Tool (BLAST) analysis, it was found that the VTW-1 sequence was similar to a 7-residue 
fragment of the interleukin-11 receptor alpha chain (IL-11RA) [191, 192]. IL-11RA is a 
transmembrane glycoprotein that binds to gp130, a cell surface molecule that is 
overexpressed in glioma cells. The mechanism by which VTW targets glioma cells is 
most likely a result of an interaction with the gp130 receptor [191]. Since the VTW-1 
sequence described above is highly hydrophobic and only has one free amine, a GGGS 
spacer sequence and five lysine residues were added to the sequence. Thus, the peptide 
used was VTWTPQAWFQWVGGGSKKKKK (VTW).  
 
2.3 Objective 
In this chapter, the synthesis and characterization of glioma-targeting NO donors 
developed from CTX and VTW is discussed. The NO donors were assessed for the 
following: 
 NO release 
 Ability to target GBM cells 
 Effects on GBM and normal cell viability and 
 Ability to be endocytosed by glioma cells 
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2.4 Materials and Methods 
2.4.1 Chemicals 
Minimum Essential Media (MEM), fetal bovine serum (FBS), L-glutamine-
penicillin-streptomycin (GPS), non-essential amino acids and 0.21% trypsin containing 
0.25% ethylenediaminetetraacetic acid (trypsin-EDTA) were obtained from Mediatech, 
Inc. (Manassas, VA). NO gas was obtained from Airgas (Atlanta, GA). Unless otherwise 
mentioned, all other chemicals were obtained from Sigma-Aldrich (St. Louis, MO). 
 
2.4.2 Cell Maintenance 
T98G and U-87MG human glioblastoma cells (American Type Cell Culture, 
Manassas, VA) were cultured in MEM with 10% FBS, 1% GPS and 1% non-essential 
amino acids at 37oC and 5% CO2
. Normal human astrocytes (NHAs, Lonza Inc. 
Walkersville, MD) were cultured in astrocyte basal media (ABM) supplemented with 
astrocyte growth medium SingleQuots (Lonza Inc. Walkersville, MD) at 37oC and 5% 
CO2. Human brain microvascular endothelial cells (HBMECs; ScienCell Research 
Laboratories, Carlsbad, CA) were cultured in Endothelial Cell Medium (ECM) 
supplemented with endothelial cell growth supplement (ScienCell Research Laboratories, 
Carlsbad, CA) at 37oC and 5% CO2. For experiments, NHAs passages 3-5, HBMECs 






2.4.3 Synthesis and characterization of NO donors 
Known amounts of CTX (Bachem Chemicals, Torrance, CA) and VTW 
(Genscript USA Inc., Piscataway, NJ) were dissolved in nanopure water (DI, 18 mΩ 
resistance) at room temperature and pH 7.4. The solution was placed in a round bottom 
flask, the atmosphere was evacuated using a vacuum pump, and then the flask was filled 
with NO gas (Fig. 2.1). Evacuating the atmosphere to create a hypoxic environment is a 
critical process for the formation of the diazeniumdiolate complex, as it prevents the 
premature conversion of NO to nitrite. After an hour, the pH of the solution was adjusted 
to 7.4 using 1M sodium hydroxide (NaOH), thereby preventing the decomposition of the 
newly formed diazeniumdiolates at low pH. Consequently, the atmosphere was evacuated 
again, and the solution was exposed to NO gas for 24 hours to ensure conversion of 
remaining amines to diazeniumdiolates [193-195]. After 24 hours, the pH of the samples 
was re-adjusted to 7.4 as before, and the samples were frozen, lyophilized and stored at -
20oC until use. These samples were designated as CTX-NO and VTW-NO.  
Figure 2.1. Reaction setup for synthesis of NO donors. An aqueous solution of the targeting 
biomolecules, CTX or VTW, was placed in a round bottom flask, and a vacuum pump was used 
to create a hypoxic environment. Subsequently, the flask was filled with NO gas and the 
biomolecules were allowed to react with the gas for 24 hours. At the end of the reaction, the 



















In order to determine the percentage conversion of amines to diazeniumdiolates 
after the reaction of the biomolecules with NO gas, a colorimetric Ninhydrin assay was 
performed. Ninhydrin reacts with free amines to form a colored complex known as 
Ruhemann's purple which has an absorbance maxima at 570 nm [196, 197]. The assay 
was performed by adding Ninhydrin solution (Spectrum Chemicals, Gardena, CA) to 
aqueous solutions of CTX, CTX-NO, VTW, VTW-NO, as well as L-leucine solutions of 
known concentrations. These mixtures were then placed in a boiling water bath for 15 
minutes and then allowed to cool for 30 minutes. Using a Beckman DTX 880 Multimode 
Plate Reader (Beckman Coulter, Drea, CA), sample absorbances were measured at a 
wavelength of 570 nm. Absorbance measurements from L-leucine samples were used to 
construct a standard curve which was used to determine the amount of amines in each 
sample. 
 
2.4.4 Characterization of NO release 
To measure NO release from the synthesized NO donors, lyophilized samples of 
CTX-NO or VTW-NO were dissolved in DI water and NO release at 37oC from the NO 
donor was quantified using an ISO-NOPF nitric oxide sensor (World Precision 
Instruments Sarasota, FL) connected to an APOLLO 1000 Free Radical Detector (World 
Precision Instruments Sarasota, FL), as shown in Fig. 2.2. The ISO-NOPF sensor is a 
combination of an NO-sensing element and a reference electrode coated with an NO-
selective membrane [198]. NO gas diffuses through the membrane and is oxidized at the 
surface of the working electrode generating, a redox current.  
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Prior to measurements with the NO donors, the ISO-NOPF sensor was calibrated 
as per manufacturer’s instructions. In brief, nitrogen was bubbled first through 10% 
solution of potassium hydroxide (KOH) and then a glass vial containing 20 ml of DI 
water. After 30 minutes, nitrogen gas was substituted with NO gas. The NO gas was then 
bubbled through the aforementioned system for ten minutes, after which the glass vial 
was sealed. NO saturated de-oxygenated DI water has been reported to have an NO 
concentration of 1.91 mM [199]. Aliquots of this saturated NO solution were used to 
calibrate the probe.  
 
Figure 2.2. Experimental setup for measuring the release of NO from CTX-NO and VTW-NO. 
The NO donor was dissolved in DI water and placed in an incubator at 37oC. The ISO-NOPF 
nitric oxide probe and a temperature probe were placed in the sample. Readings were collected by 
the APOLLO 1000 free radical detector connected to the probes. 
 
2.4.5 Verification of glioma targeting ability 
In order to determine if VTW and CTX retained their tumor targeting abilities 
following the reaction of amines with NO gas, the biomolecules were first labeled with 
fluorescein isothiocyanate (FITC). In brief, the biomolecules were dissolved in DI water 
and reacted with a two-fold molar excess of a 0.1 mM solution of FITC in 0.1 M sodium 
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bicarbonate buffer (pH 9.0). The FITC solution was added dropwise to the solution of 
CTX or VTW and allowed to react for two hours in the dark. The FITC labeled 
biomolecules were then dialyzed for two hours against DI water and subsequently reacted 
with NO for 24 hours to neutralize the charge on any unreacted amines. The final 
products, designated as CTX-FITC and VTW-FITC, were frozen, lyophilized and stored 
at -20oC until use.  
T98Gs, U-87MGs, NHAs and HBMECs were seeded in black-walled 96-well 
plates at a density of 25,000 cells/cm2. After allowing the cells to adhere for 24 hours, 
they were incubated for 30 minutes with FITC-labeled biomolecules. All cell types were 
exposed to 5 µM of FITC-reacted amines. This VTW/CTX concentration is equivalent to 
exposure of cells to 10 µM of NO. After 30 minutes, the media was removed and the 
cells were washed three times with phosphate buffered saline (PBS, pH 7.4) before fresh 
media was added. The ability of the fluorescently labeled biomolecules to adhere to the 
different cell types was visualized using a Leica DMI 4000B fluorescent microscope 
equipped with a Hamamatsu ORCA-ER digital camera (Leica Microsystems, Inc., 
Bannockburn, IL). A minimum of three pictures were taken per well. Furthermore, the 
fluorescence in each image was quantified using Image J software. In order to ensure 
changes in fluorescence were not due to changes in cell proliferation, a separate 
experiment was conducted in which cells were seeded at the aforementioned density and 
after 24 hours cells were trypsinized and counted using a Beckman z1 Particle Counter 





2.4.6 Effect of NO on cell viability  
T98Gs, U-87MGs, NHAs and HBMECs were seeded in 96-well plates at a 
density of 25,000 cells/cm2. Cells were allowed to adhere for 24 hours, after which they 
were incubated with varying concentrations of CTX-NO or VTW-NO such that each cell 
type was exposed to 0, 10, 20 and 40 µM of NO. In control experiments, T98G and U-
87MG cells were incubated with equivalent concentrations of VTW or CTX (not reacted 
with NO). After 48 hours, the media was aspirated and the cultures were rinsed with PBS 
to remove dead cells. The remaining cells were removed from the culture surface using 
trypsin-EDTA and counted using a Beckman z1 Particle Counter (Beckman Coulter, 
Drea, CA). Cell viability was calculated using the following formula:  
Cells counted after incubation with NO donor
Cell viability    100
Cells counted after incubation with DI
   
Similar cell viability experiments were conducted with SNAP, which served as a 
non-targeting NO control. In brief, T98Gs and U-87MGs were seeded in 96-well plates at 
a density of 25,000 cells/cm2. After 24 hours, cells were incubated for 48 hours with 0-
200 µM solutions of SNAP in water. SNAP has been used in a variety of studies to 
inhibit glioma cell growth [19, 143, 158, 200-202]. It releases 1 mole of NO per mole of 
SNAP spontaneously under physiological conditions, with a reported half life of 4-5 
hours [203, 204]. After 48 hours, as before, cells were removed from culture surface and 
counted.  
In an alternate experiment to measure cell viability, after a 48 hour incubation 
with CTX-NO or VTW-NO, a Live/Dead assay (Invitrogen, Carlsbad, CA) was used to 
visualize viable cells. In brief, the cells were washed three times and then incubated with 
2 μM calcein-AM and 4 μM ethidium homodimer-1. After 30 minutes of incubation, a 
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Leica DMI 4000B fluorescent microscope equipped with a Hamamatsu ORCA-ER digital 
camera (Leica Microsystems, Inc., Bannockburn, IL) was used to visualize green and red 
fluorescence emitted by the live and dead cells, respectively. A minimum of three 
pictures were taken per well. The number of cells stained red and green were counted to 
calculate the percentage of dead cells.  
 
2.4.7 Effect of an NO scavenger on cytotoxicty of CTX-NO 
T98Gs and U-87MGs were seeded in 96-well plates at a density of 25,000 
cells/cm2. After allowing cells to adhere for 24 hours, the cells were incubated with either 
MEM or MEM containing hemoglobin (HB), an NO scavenger. Immediately following 
the initial incubation, the cells were exposed to CTX-NO or VTW-NO such that cells 
were incubated with 0, 10 or 20 µM NO. After 48 hours, the cultures were rinsed to 
remove dead cells and the remaining cells were removed from the culture surface. 
Viability was measured as described in section 2.4.6.   
 
2.4.8 Endocytosis of NO donors 
Glass coverslips were coated with 0.5% gelatin for 2 hours, and T98G and U-
87MG cells were seeded on the coverslips at a density of 25,000 cells/cm2. After 24 
hours, cells were incubated with CTX-FITC or VTW-FITC, as described in section 2.4.5. 
After the 30 minute incubation, cells were washed three times with PBS. The cells were 
then incubated with 5µg/ml of orange plasma membrane stain (Invitrogen, Carlsbad, CA) 
for 5 minutes at 37oC. Subsequently, the cells were fixed with 4% formaldehyde for 10 
minutes. Next, cells were incubated with 600 nM of 4',6-diamidino-2-phenylindole, 
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dihydrochloride (DAPI) stain for 5 minutes. The coverslips were then mounted on a glass 
slide and visualized using a Zeiss LSM 510 UV Confocal Microscope (Carl Zeiss Inc, 
Peasbody, MA) with the appropriate filters. 
 
2.4.9 Statistical Analysis 
All experiments were carried out minimally in triplicate. Different conditions 
were compared using an analysis of variance (ANOVA), with p-values less than 0.02 
considered to be statistically significant.   
 
2.5 Results 
2.5.1 Characterization of NO donor 
In order to measure the efficacy of the reaction with NO gas, the Ninhydrin assay 
was used to detect free amines on biomolecules in solutions, both before and after the 
hypoxic reaction with NO gas. Before the reaction with NO gas, 6.9 ± 0.26 amines/mole 
CTX (85.7 ± 3.31%) were detected, whereas after the 24 hour reaction with NO gas, 0.00 
± 0.00 amines/ mole CTX were detected. Similarly, 3.6 ± 0.07 amines/mole VTW (72.5 ± 
1.42%) were detected before the reaction of VTW with NO gas, whereas after the 
reaction 0.05 ± 0.08 amines/mole VTW (0.91 ± 1.58%) were detected.  
 
2.5.2 Characterization of NO release  
As discussed in Chapter 1, diazeniumdiolates are able to dissociate in aqueous, 
acidic and neutral environments to release two moles of NO. Therefore, in order to 
36 
 
measure the decomposition of diazeniumdiolates, samples of CTX-NO and VTW-NO 
were dissolved in DI water and the NO release rates were measured using an NO probe. 
The NO probe is covered in an NO selective membrane and hence only detects NO and 
not the by-products of NO degradation that could be present in the solution.  
The measurements from the NO-specific microsensor demonstrated that CTX-NO 
and VTW-NO had similar instantaneous NO release profiles. Peak NO release from 
CTX-NO was found to be after 3.93 hours of dissolution in DI water (Fig. 2.3A) whereas 
peak NO release from VTW-NO was after 4.45 hours (Fig. 2.3C). Cumulative release 
profiles for both NO donors, CTX-NO (Fig. 2.3B) and VTW-NO (Fig. 2.3D), were 
calculated using the results from the NO probe and the Ninhydrin assay. The cumulative 
release profiles showed that CTX-NO released 91.05% ± 1.30 of the expected NO in the 
first 72 hours (Fig. 2.3B), while VTW-NO released 87.9% ± 0.26 of the expected NO 
within the same time period (Fig. 2.3D). Further analysis also showed that CTX-NO and 




Figure 2.3. (A) Instantaneous NO release from CTX-NO at pH 7.4 in DI water at 37oC. Peak NO 
release was observed after 3.93 hours and NO release continued for at least 72 hours. (B) 
Cumulative release profile for CTX-NO based on results of Ninhydrin assay and instantaneous 
NO release profiles. Over 90% of the expected NO was released in the first 72 hours and CTX-
NO has a half life of 19.2 hours. (C) Instantaneous NO release from VTW-NO at pH 7.4 in DI 
water at 37oC. Peak NO release was observed after 4.45 hours and NO release continued for at 
least 72 hours. (D) Cumulative release profiles for VTW-NO based on results of Ninhydrin assay 
and instantaneous NO release profiles. Over 85% of the expected NO was released in the first 72 
hours and VTW-NO has a half life of 24.3 hours. 
 
2.5.3 Verification of glioma targeting ability 
In order to determine whether the biomolecules retained their targeting ability 
after the reaction of amines, the biomolecules were first tagged with FITC, incubated 
with cells and then visualized using fluorescence microscopy. It was visually determined 
that the FITC-labeled biomolecules, when incubated with T98G, U-87MG, NHA and 
HBMEC cells, bound preferentially to the glioma cell lines and only minimal binding to 
the NHAs and HBMECs was observed (Fig. 2.4A). This qualitative assessment suggested 




















































































































target glioma cells. Thus, it is inferred that the reaction with NO, which is a much smaller 
molecule than FITC, will not hinder the specificity of the biomolecules.  
 
 
Figure 2.4. (A) Fluorescent images of cell cultures showing binding of FITC labeled CTX (top 
row) and VTW (bottom row) to different cell types after 30 minute incubation with the 
biomolecules Scale bar = 10 µM. Qualitative analysis shows that both biomolecules bind to 
glioma cells lines, T98G and U-87MG, very efficiently whereas non-tumor cell lines, NHAs and 
HBMECs, show only minimal binding. Relative fluorescence of cells incubated with 
fluorescently tagged with (B) CTX and (C) VTW, quantified using Image J. Both CTX and VTW 
show significantly higher binding to glioma cells in comparison to non-tumor cell lines, NHA and 
HBMEC. *p < 0.02 compared to NHA, n = 5. 
 
In order to measure differences in the binding of FITC-labeled biomolecules to 
the different cell types, the relative fluorescence detected for each cell type was 
quantified using Image J software. From this quantitative analysis, it was determined that 
relative to the fluorescence detected in NHA cultures (normalized to 1.00 ± 0.21), labeled 
CTX bound to HBMECs had an intensity of 1.01 ± 0.15, while T98G and U-87MG 
cultures had fluorescence intensities of 5.78 ± 1.07 and  3.46 ± 0.99, respectively (Fig. 
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2.4B). Similarly, the differences in the binding of labeled VTW were quantified by 
showing that relative to fluorescence measured in NHAs (again normalized to 1.00 ± 
0.11) and in HBMECs (1.30 ± 0.16), T98Gs (4.30 ± 0.99) and U-87MGs (3.42 ± 0.73) 
displayed significantly higher fluorescence, and hence binding, to VTW-FITC (Fig. 
2.4C). Cell proliferation was also monitored during this experiment, and no significant 
increase in cell number was observed; the increased fluorescence is only due to the 
preferential binding of CTX-NO and VTW-NO to glioma cells. 
 
2.5.4 Effect of NO on cell viability  
Cells were incubated with either CTX-NO or VTW-NO for 48 hours, trypsinized, 
and counted to determine the effect of the NO donors on the viability of different cell 
types. In control experiments, the cytotoxicity of VTW and CTX was also investigated. 
No significant changes in glioma cell viability were observed after incubation with VTW 
or CTX that were not reacted with NO (Fig. 2.5). 
 
 
Figure 2.5. Effect of biomolecules, (A) CTX and (B) VTW on the cell viability of glioma cell 
lines, T98G and U-87MG. Legend refers to (A) CTX and (B) VTW concentrations. Data is 
presented as a percentage of the number of cells that were incubated with only media. Gioma cell 




 At an NO concentration of 10 µM, (the lowest concentration used for these 
experiments) CTX-NO was effective in reducing cell viability to 68.6 ± 14.4% and 72.7 
± 6.5% of the control cell number in T98G and U-87MG cells respectively (Fig. 2.6A). 
Conversely, NHA and HBMEC viability remained above 92.5 ± 3.0% at the same NO 
concentration.  
 
Figure 2.6. Effect of targeted NO donors, (A) CTX-NO and (B) VTW-NO, on the cell viability 
of glioma cell lines, T98G and U-87MG, and normal cell types, NHA and HBMEC. Data is 
presented as a percentage of the number of cells that were incubated with NO free media. The 
legend refers to NO concentrations corresponding to CTX concentrations of 0, 0.7, 1.5 and 2.9 
µM  and VTW concentrations of 0, 1.3, 2.7 and 5.3 µM. Both donors show a dose dependant 
effect on glioma cell viability and have no significant effect on the normal cell types at the lower 
NO concentrations. Comparing the effect of the two donors at a median concentration of 20 µM it 
is observed that CTX-NO is more efficient in reducing glioma cell viability in comparison to 
VTW-NO. *p < 0.02, n = 4.  
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At a higher NO concentration of 20 µM, CTX-NO reduced T98G and U-87MG 
cell viability to 27.4 ± 5.4% and 26.8 ± 5.1%, respectively. At this NO concentration 
NHA cells had a viability of 86.8 ± 16.9% and HBMECs had a viability of 87.5 ± 2.9% 
(Fig. 2.6A). At the highest NO concentration of 40 µM, released by CTX-NO, glioma 
cell viability was substantially reduced to 3.60 ± 0.9% and 3.1 ± 2.9% of the control cell 
number in T98G and U-87MG cells, respectively. However, at this high NO 
concentration NHA and HBMEC viability was also reduced to 20.1 ± 1.3% and 47.7 ± 
3.5% respectively.  
Although VTW-NO showed a similar effect on the viability of the different cell 
lines, it was not as efficient as CTX-NO in decreasing tumor cell viability. At the lowest 
concentration of NO, 10 µM, VTW-NO did not significantly change glioma cell viability 
which was measured to be 97.9 ± 10.9% and 85.9 ± 7.9% of the control cell number in 
T98G and U-87MG cells, respectively (Fig. 2.6B). At a higher NO concentration of 
20µM, VTW-NO was able to reduce the cell viability of T98G cells and U-87MG cells to 
67.4 ± 6.5% and 57.1 ± 7.2%, respectively (Fig. 2.6B). At this same concentration, NHA 
viability was not reduced and was measured to be 101 ± 11.9% of the control cell 
number. However, HBMEC viability was reduced to 78.0 ± 3.6% at the aforementioned 
concentration. At the highest NO concentration of 40 µM, the viability of the T98G cells 
was significantly reduced to 33.1 ± 6.9% and U-87MG viability was reduced to 30.8 ± 
1.5%. As opposed to the lower concentrations, at an NO concentration of 40 µM donated 
by VTW-NO, the viability of the NHAs was also reduced to 86.0 ± 4.1% (Fig. 2.6B  
In order to visualize the effect of NO on cell viability, following a 48 hour 
incubation with either VTW-NO or CTX-NO, cells were stained with a mixture of 
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calcein-AM and ethidium homodimer-1. Non-fluorescent calcein-AM is converted to 
green fluorescent calcein by viable cells, while ethidium homodimer-1, which is a 
fluorescent red DNA stain, is only able to permeate dead cells [205]. That is, the mixture 
stains live cells green and dead cells red.  
For these experiments, cells were exposed to an NO concentration of 10 μM, 
since at higher concentration massive tumor cell death occurred, resulting in a majority of 
the cells detaching from the surface. Using fluorescence microscopy, cell viability was 
visualized and the percentage of cells stained red by the ethidium homodimer-1 (dead 
cells) was calculated for each cell type. Even at a low NO concentration, 13.3 ± 6.4% of 
the adherent T98G cells were stained red after the CTX-NO treatment, whereas without 
the CTX-NO treatment only 0.4 ± 0.5% of the adherent T98G cells were stained red (Fig. 
2.7A). Similarly, when U-87MG cells were incubated with CTX-NO 27.8 ± 8.5 % of the 
adherent U-87MG cells stained red (Fig. 2.7B). NHA (Fig. 2.7C) and HBMECs (Fig. 






Figure 2.7. (A) T98Gs (B) U-87MGs (C) NHAs and (D) HBMECs incubated with 10 µM of NO 
donated by CTX-NO for 48 hours and then with a mixture of calcein-AM and ethidium 
homodimer-1. Non-fluorescent calcein-AM is converted to green fluorescent calcein by viable 
cells, whereas ethidium homodimer-1 is a fluorescent red DNA stain that is only able to permeate 
dead cells. T98G and U-87MG glioma cells, show significant increase in the proportion of cells 
that are non-viable after the CTX-NO treatment. NHAs and HBMECs show no significant 
changes with or without the CTX-NO treatment. *p < 0.01compared to cells stained green, #p < 
0.01 compared to cells stained red, n = 5-9. 
 
Similarly, cells were incubated with VTW-NO for 48 hours such that T98G, U-
87MG, NHA and HBMECs were exposed to 10 μM of NO, and then stained with a 
mixture of calcein-AM and ethidium homodimer-1. After T98G cells were exposed to 
VTW-NO treatment, 17.0 ± 7.6% of the cell population stained red indicating cell death 
(Fig. 2.8A). In comparison, when cells were not exposed to VTW-NO only 0.6 ± 0.7% 
of the cell population were dead. Similarly, 6.7 ± 4.6% of the U-87MG cells exposed to 
VTW-NO were stained red, whereas only 1.4 ± 1.7% of the U-87MG cells not exposed 
44 
 
to VTW-NO were stained red (Fig. 2.8B). NHAs (Fig. 2.8C) and HBMECs (Fig. 2.8D) 
showed no significant changes in cell death when incubated with or without VTW-NO. 
 
 
Figure 2.8. (A) T98Gs (B) U-87MGs (C) NHAs and (D) HBMECs incubated with 10 µM of NO 
donated by VTW-NO for 48 hours and then with a mixture of calcein-AM and ethidium 
homodimer-1. T98G and U-87MG, glioma cells, show significant increase in the proportion of 
cells that are non-viable after the CTX-NO treatment. Conversely NHAs and HBMECs show no 
significant changes with or without the CTX-NO treatment. *p < 0.01compared to cells stained 
green, #p < 0.01 compared to cells stained red, n = 5-9. 
 
To compare the effects of a targeted NO donor and a non-targeting NO donor, 
glioma cells were incubated with various concentrations of SNAP for 48 hours. It was 
observed that U-87MG cells were more sensitive to the toxic effects of NO released by 
SNAP, with the cell viability decreasing to 60.0 ± 8.2% of the control cell number at an 
NO concentration of 50 µM (Fig. 2.9). T98G cell viability was not significantly reduced 
until the cells were exposed to a higher NO concentration of 100 µM. At 200 µM, the 
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highest NO concentration tested, T98G and U-87MG cell viability was reduced to 62.8 ± 
22.0% and 30.1 ± 5.1% of the control cell number, respectively (Fig. 2.9). 
 
 
Figure 2.9. Glioma cell viability, T98G and U-87MG, after 48 hour incubation with different 
doses of non-targeting NO donor, SNAP. U-87MG cells begin to show significant decrease in cell 
death at NO concentrations of 50 µM and higher, whereas T98G cell viability decreases at 
concentrations of 100 µM and higher. Thus showing that much higher doses of NO are required 
in comparison to the doses required with targeted NO donors. *p < 0.05, n = 3-5 
 
2.5.5 Effect of NO scavenger on cytotoxicty of NO donors 
In order to determine whether the CTX-NO and VTW-NO released NO in the 
extra- or intracellular space, glioma cells were treated with NO donors in the presence of 
hemoglobin (HB), an extracellular NO scavenger. Adding HB prior to the CTX-NO 
treatment did not result in neutralization of the cytotoxic effects of the NO donor on 
T98G or U-87MG cells (Fig. 2.10). When HB was added to the glioma cells prior to the 
VTW-NO treatment, slight neutralization of the cytotoxic effects was observed in T98G 

































Figure 2.10. Cell viability of (A) T98G and (B) U-87MG after 48 hour incubation with CTX-NO 
in the presence of hemoglobin. The NO scavenger, hemoglobin did not mitigate the cytotoxic 
effects of CTX-NO, suggesting that the NO released is after the donor has been endocytosed. *p 
< 0.02, n = 3-5. 
 
 
Figure 2.11. Cell viability of (A)T98G and (B)U-87MG after 48 hour incubation with VTW-NO 
in the presence of hemoglobin. Slight neutralization of the cytotoxic effects of VTW-NO 
was observed in T98G cells but no mitigation of toxic effects was seen in the U-87MG 
cells, suggesting that most of the NO donor is endocytosed. *p < 0.02, n = 3-5 
 
2.4.6 Endocytosis of NO donors 
Minimal attenuation of the cytotoxic effects of CTX-NO and VTW-NO by HB, 
indicated that only minimal amount of NO, from both of the NO donors, was released in 
the extracellular space. Thus it can be deduced that the NO donors were efficiently 
endocytosed by glioma cells. Nonetheless, a visual assessment of the endocytosis was 
also done using confocal microscopy. T98G and U-87MG cells were incubated with 
either CTX-FITC or VTW-FITC for 30 minutes, and afterwards the cell membranes and 
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nuclei were stained and images were taken using a confocal microscope. Incubation with 
CTX-FITC and VTW-FITC resulted in observations of green fluorescence in the 
intracellular space of T98Gs (Fig. 2.12) and U-87MGs (Fig. 2.13). Since NO is a much 
smaller molecule than FITC, it can be assumed that NO would not hinder the ability of 
the glioma cells to endocytose the biomolecules. 
 
Figure 2.12. Confocal fluorescent images of T98G cells showing endocytosis of CTX-FITC 
(middle row) and VTW-FITC (bottom row) after a 30 minute incubation with biomolecules. The 
top row shows T98G cells incubated with FITC alone. Free FITC did not bind to T98G cells; it is 
only the conjugation of FITC with either CTX or VTW that results in the green fluorescence in 
the intracellular space. Red: dye stained membrane; Blue, DAPI-stained nuclei; Green: FITC. 




Figure 2.13. Confocal fluorescent images of U-87MG cells showing endocytosis of CTX-FITC 
(middle row) and VTW-FITC (bottom row) after a 30 minute incubation with biomolecules. The 
top row shows U-87MG cells incubated with FITC alone. Free FITC did not bind to U-87MG 
cells; it is only the conjugation of FITC with either CTX or VTW that results in the green 
fluorescence in the intracellular space. Red: dye stained membrane; Blue, DAPI-stained nuclei; 
Green: FITC. Scale bar = 20 µm 
 
2.6 Discussion 
As discussed in Chapter 1, although it is well established that NO plays a 
ubiquitous role in malignant gliomas, it is still debated whether NO promotes or inhibits 
tumor growth [126, 141, 152, 206, 207]. Using two glioma-targeting NO donors, it was 
demonstrated that NO can indeed inhibit glioma cell proliferation in two different brain 
tumor cell lines, T98G and U-87MG. In vitro studies demonstrated that when glioma 
cells were exposed for 48 hours to 20 µM of NO released from CTX-NO, glioma cell 
viability is reduced to less than 30% of the untreated control, whereas NHA and HBMEC 
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viability remained above 80%. At the same NO concentration, VTW-NO reduced glioma 
cell viability to 57% of the control, but NHA and HBMEC viability remained above 75%. 
The fact that HBMEC and NHA viability remained above 75% at an NO concentration of 
20 µM (donated by either CTX-NO or VTW-NO), demonstrates that both donors are 
targeting glioma cells and the control cells are exposed to only minimal doses of NO. 
Furthermore control experiments in which cells were incubated with VTW or CTX 
demonstrated that the targeting sequences themselves are innocuous and thus the toxic 
effects are due to the conjugation of NO to the biomolecules.  
Furthermore, in control experiments using SNAP, a non-targeting NO donor, it 
was shown that without targeting, NO doses upward of 50 µM are required to induce 
cytotoxic effects. This corroborates previous studies that have shown that non-targeted 
diazeniumdiolates such as SPER/NO are required at concentrations of 200 µM or higher 
to significantly decrease glioma cell viability [19]. Even higher concentrations, 20 mM 
and higher, of other non-targeted diazeniumdiolates (PROLI/NO and diethylamine 
NONOate (DEA/NO)), were required to significantly decrease glioma cell viability [19].  
NO, as a result of its reactive nature, has a relatively small sphere of influence, 
extending approximately 100 µm from its origin [125]. Thus, the targeted NO donors are 
able to deliver NO within a closer proximity to the tumors cells, as well as intracellularly, 
and are more effective in utilizing the cytotoxic effects of NO in comparison to non-
targeted NO donors. As a consequence, the amount of NO required to produce cytotoxic 
effects is decreased ten-fold. Importantly, the targeted delivery of NO dramatically 
reduces toxic effects to NHAs and HBMECs. At a median concentration of CTX-NO and 
VTW-NO, even though glioma cell viability is significantly reduced, NHA and HBMEC 
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cell viability is not significantly affected. By fluorescently tagging CTX and VTW, it was 
demonstrated that these biomolecules retain their tumor targeting abilities even after the 
reaction of amines with FITC. Thus, it stands to reason that the biomolecules retain their 
targeting ability even after the reaction of NO with amines. Furthermore, CTX-FITC and 
VTW-FITC are able to bind to cells within 30 minutes of exposure, well before the peak 
NO release of either of the donors, thereby ensuring that the majority of the NO is 
released after localization of the donors to glioma cells.  
Uptake of the bound molecules by endocytosis is most certainly occurring early in 
the incubation period and perhaps enhancing the effects of the NO donors through 
intracellular delivery of NO to tumor cells. In order to assess the endocytosis of these 
biomolecules, two experiments were carried out. First, the NO donors CTX-NO and 
VTW-NO were incubated with cells in the presence HB. HB is a well documented NO-
scavenger and has been shown to neutralize the cytotoxic effects of NO donors on glioma 
cells [175, 208]. HB is not endocytosed by glioma cells; therefore, it acts as an NO 
scavenger only in the extracellular space and is unable to scavenge NO that is released 
inside the cells [209]. It was found that the addition of HB did not mitigate the cytotoxic 
effects of CTX-NO and only slightly mitigated the effects of VTW-NO. This suggests 
that most of the NO is being released within the cell. To further asses this phenomena, the 
uptake of CTX-FITC and VTW-FITC was visualized by confocal microscopy. It was 
found that both biomolecules are endocytosed by the glioma cells, as evidenced by 
fluorescence observed in the intracellular space of both T98G and U-87MG cells. This 
data is in agreement with previous studies that have shown the uptake of CTX-conjugated 
nanoparticles and VTW-conjugated β-galactosidase by glioma cells [115, 191].  
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 In comparing the cytotoxic effects of the two NO donors, at an NO concentration 
of 40 µM, CTX-NO reduced the viability of GBM cells to less than 5% of the control, but 
with VTW-NO the GBM viability remained 30-35% of the control. Furthermore, when 
incubated with HB some neutralization of the cytotoxic effects of VTW-NO, albeit 
minor, was observed. Based on these observations, CTX-NO was found to be a more 
efficient GBM-targeting NO donor. Control studies showed that CTX alone does not 
induce toxic effects and therefore it is hypothesized that CTX-NO is able to deliver NO 
more efficiently to glioma cells, or acts synergistically with NO to decrease cell viability. 
Thus, further studies investigating the effects of targeted NO delivery on GBM 




CHAPTER 3: EFFECT OF TARGETED NO DELIVERY ON THE 
CHEMOSENSITIVITY OF GLIOMA CELLS 
 
3.1 Summary  
GBM is among the most chemoresistant of human tumors, resulting in tumor 
reoccurrence despite surgery, radiation, and chemotherapy. TMZ and BCNU are the two 
most commonly used chemotherapeutics for the treatment of GBM. However, a 
significant percentage of patients do not respond to either chemotherapeutic, and 
therefore the mean survival of patients remains under two years. Herein, CTX-NO, one of 
the targeted NO donors characterized in Chapter 2, was used to deliver NO specifically to 
glioma cells and induce chemosensitivity. NO, when delivered via a targeted donor 
decreased levels of MGMT, a DNA repair enzyme, as well as levels of  p53, a protein 
that can activate DNA repair. As a consequence, both T98Gs, the more chemoresistant 
glioma cell line, and U-87MGs are able to respond to lower doses of TMZ and BCNU. 
Although all of the effects of NO delivery and subsequent chemosensitivity are yet to be 
elucidated, this work suggests that the use of targeted NO to sensitize cells towards 
chemotherapeutics holds great potential as an adjuvant in the multimodal treatment of the 
numerous tumors that are normally unresponsive to chemotherapy. 
 
3.2 Introduction 
GBM is among the most difficult tumors to treat due to a lack of response to 
chemotherapeutics. For the past three decades, the standard of care for GBM patients has 
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been surgery followed by radiation and/or chemotherapy [211]. Chemotherapeutics are 
generally classified as either cytostatic or cytotoxic [42]. Cytostatic drugs inhibit cell 
growth, whereas cytotoxic agents cause cell death via a variety of pathyways, including 
DNA alkylation, DNA cross-linkage, DNA strand breaks, and mitotic spindle disruption 
[42, 212]. As mentioned in Chapter 1, GBM treatment plans involve orally administering 
temozolomide (TMZ) in conjugation with radiation therapy [3]. TMZ is a cytotoxic 
alkylating agent which spontaneously hydrolyzes at physiological pH into 3-methyl-
(triazen-1-yl)imidazole-4-carboxamide (MTIC), the active degradation product, which in 
turn induces methylation of various locations on DNA (Fig. 3.1A) [55].  
An alternative GBM treatment involves the use of BCNU-loaded Gliadel® wafers. 
In comparison to the oral administration of TMZ, this unique drug delivery system 
utilizes biodegradable wafers that are placed in the tumor cavity after resection; the drug 
is delivered intracranially as the polymer degrades. BCNU, prior to the approval of 
Gliadel® wafers in 2003, was administered intravenously. BCNU acts via multiple 
cytotoxic actions, including carbamoylation and alkylation of DNA to kill tumor cells 
[45]. Despite these advances in glioma therapy, only modest improvements in patient 
survival have been observed, and median patient survival remains less than 2 years [213-
215]. Hence, there is a dire need for improvement in the efficacy of these 





Figure 3.1.  Commercially available (A) temozolomide (TMZ) and (B) carmustine (BCNU) are 
shown along with their chemical structures. 
 
The resistance of tumor cells to the biological effects of alkylating and 
chloroethylating agents like TMZ and BCNU is partially due to the presence of the DNA 
repair protein O6-methylguanine-DNA methyltransferase (MGMT) [216, 217]. MGMT is 
a 22 kDA protein that repairs alkylation of O6–G on DNA strands by transferring the 
methyl group to an internal cysteine acceptor residue [2, 7, 216]. Alkylation, if left 
unrepaired, results in the induction of apoptosis; thus, MGMT serves as a defense 
mechanism against alkylating agents, including chemotherapeutics. The cytotoxicity of 
TMZ and BCNU has been correlated with intracellular levels of MGMT and high levels 
of MGMT are associated with chemoresistant gliomas [7, 218-221]. Furthermore, 
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inactivation of MGMT, via inhibitors of the enzyme, has been shown to increase tumor 
cell chemosentivity towards both BCNU and TMZ [222].  
In addition to MGMT another biomolecule that plays an important role in 
determining chemosensitivity is the protein p53. The actions of p53 play a critical role in 
maintaining the integrity of the genome and determining cellular response, either 
activating DNA repair mechanisms or triggering apoptosis after exposure to damaging 
stimuli such as radiation or chemotherapy [223, 224]. However, more than half of all 
human cancers contain mutations of the p53 protein, which results in an increase of 
oncogenic functions, including decreased chemosensitivity [225, 226]. Despite the 
availability of a number of chemotherapeutics for GBM treatment, it is among the most 
chemoresistant tumors, and therefore it is of great interest to develop a therapeutic that in 
addition to having cytotoxic properties can enhance the chemosensitivity of glioma cells.  
 
3.3 Objective 
In this chapter, work on investigating the effects of a glioma-targeting NO donor 
on the chemosensitivity of glioma cells to TMZ and BCNU is discussed. Targeted NO 
pretreatment coupled with chemotherapy was assessed for effects on: 
 Glioma and control cell viability 
 MGMT expression in glioma cells  
 p53 expression in glioma cells  
 Glioma cell invasion 




3.4 Methods and Materials  
3.4.1 Chemicals 
Minimum Essential Media (MEM), fetal bovine serum (FBS), L-glutamine-
penicillin-streptomycin (GPS), trypsin-EDTA and non-essential amino acids were 
obtained from Mediatech, Inc. (Manassas, VA). NO gas was obtained from Airgas 
(Atlanta, GA), chlorotoxin (CTX, purity > 87%) was obtained from Bachem Chemicals 
(Torrance, CA). Unless otherwise mentioned, all other chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO). 
 
3.4.2 Cell Maintenance 
T98G and U-87MG human glioblastoma cells (American Type Cell Culture, 
Manassas, VA), were cultured in MEM with 10% FBS, 1% GPS and 1% non-essential 
amino acids at 37oC and 5% CO2. Normal human astrocytes (NHAs; Lonza Inc. 
Walkersville, MD) were cultured in astrocyte basal media (ABM) supplemented with 
astrocyte growth medium SingleQuots (Lonza Inc. Walkersville, MD) at 37oC and 5% 
CO2. Human brain microvascular endothelial cells (HBMECs; ScienCell Research 
Laboratories, Carlsbad, CA) were cultured in Endothelial Cell Medium (ECM) 
supplemented with endothelial cell growth supplement (ScienCell Research Laboratories, 
Carlsbad, CA) at 37oC and 5% CO2. For experiments, NHAs passages 3-5, HBMECs 






3.4.3 NO donor synthesis  
CTX-NO was synthesized as described in section 2.4.3. As before, reacted 
samples were freeze dried and stored at -20oC until use. At the time of experiments, these 
samples, designated CTX-NO, were dissolved in DI to form solutions such that cells 
were exposed to the desired concentration of NO.  
 
3.4.4 Chemosensitivity and Viability studies 
T98G and U-87MG cells were seeded in 96-well plates at a density of 25,000 
cells/cm2. After allowing cells to adhere for 24 hours, the cells were incubated for 2 hours 
with CTX-NO, to allow the NO donor to bind to the glioma cells. The concentration of 
CTX-NO was adjusted such that each cell type was exposed to 0-5 µM of NO. After 2 
hours, the cells were washed with PBS and treated with either BCNU (0-600 µM) or 
TMZ (0-800 µM) for 48 hours. Under control conditions, cells were pretreated with CTX 
(not reacted with NO gas) or left untreated. After 48 hours, the cultures were rinsed 
thoroughly to remove dead cells; the remaining adherent cells were removed from the 
culture surface using trypsin-EDTA and counted using a Beckman z1 Particle Counter 
(Beckman Coulter, Drea, CA). Viability was calculated as described in section 2.4.6. 
Based on the results from these studies, a BCNU concentration of 75 µM and a 
TMZ concentration of 50 µM were chosen for further analysis. The NO range was also 
reduced to 0-2 µM. In order to study the differences in the CTX-NO pretreatment on 
glioma and control cells, further viability studies were performed. T98G, U-87MG, 
NHAs and HBMECs were seeded in 96-well plates at a density of 25,000 cells/cm2. After 
allowing cells to adhere for 24 hours, the cells were incubated for 2 hours with CTX-NO 
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to allow the NO donor to bind to the glioma cells. The cells were then washed with PBS 
and treated with either BCNU (75 µM) or TMZ (50 µM) for 48 hours. After 48 hours 
viability was measured as described previously.  
 
3.4.5 Analysis of active MGMT Levels 
T98G cells were seeded in 24-well plates at a density of 25,000 cells/cm2. After 
24 hours, the cells were treated with CTX-NO for 2 hours, washed and then incubated 
with BCNU or TMZ for 48 hours. At the end of the incubation period, the cells were 
washed and removed from the well plate using trypsin-EDTA. After which, the cells 
were centrifuged at 1700 rpm for 4 minutes, the media was removed, and the cells were 
resuspended in sterile DI water. Subsequently, the cells were lysed in three freeze-thaw 
cycles.  
Cell debris was removed by centrifugation and the resulting supernatant was used 
to quantify MGMT using an enzyme-linked immunosorbent assay kit (ELISA; USCN 
Life Sciences, Inc Wuhan, China) according to the manufacturer’s instructions. In brief, 
samples were added to a 96-well plate, pre-coated by the manufacturer with a monoclonal 
antibody specific to MGMT, for 2 hours. Next, a biotin-conjugated polyclonal antibody 
specific for MGMT was added to the wells for 1 hour. After several washes, avidin-
conjugated horseradish peroxidase (HRP) was added to the wells. Finally, the 
chromogenic HRP substrate, 3,3',5,5'-tetramethylbenzidine (TMB), was added to detect 
HRP. The sample absorbances were measured at a wavelength of 450 nm using a DTX 
880 Multimode Detector (Beckman Coulter, Drea, CA) and compared to a set of 
standards of known concentration to determine MGMT levels in each sample.  
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In addition, the total protein content of each sample was measured using a 
bicinchoninic acid (BCA) protein assay as per manufacturer’s instructions (Thermo 
Scientific Pierce, Rockford, IL). In brief, reagent A, containing sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M NaOH, was mixed in 
a ratio of 50:1 with 4% cupric sulfate to prepare the working reagent. 25μL of the cellular 
extracts were mixed with 200 μL of the working reagent and incubated at 37°C for 30 
minutes. Standards containing known concentrations of bovine serum albumin (BSA) 
were also reacted with the working reagent. After allowing the samples to cool to room 
temperature, absorbances were measured at a wavelength of 560 nm using a DTX 880 
Multimode Detector (Beckman Coulter, Drea, CA). Absorbance measurements from 
BSA samples were used to construct a standard curve, from which the concentrations of 
the samples were detected.  
 
3.4.6 Assessment of p53 Levels 
T98G and U-87MG cells were seeded in black walled 96-well plates at a density 
of 25,000 cells/cm2. As before, after 24 hours the cells were treated with CTX-NO for 2 
hours, washed and then incubated with BCNU or TMZ. After 48 hours, the cells were 
fixed with 4% formaldehyde and intracellular p53 levels were measured using an In-Cell 
ELISA Colorimetric Detection Kit (Thermo Scientific Pierce, Rockford, IL), performed 
per manufacturer’s instructions (Fig. 3.3). In brief, cells were permeabilized using 
Surfact-Amps X-100 detergent, which was then quenched using a 1% hydrogen peroxide 
solution. Nonspecific protein adsorption was prevented through incubation with a 
blocking buffer. Samples were then incubated with a p53-specific primary antibody 
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followed by incubation with a HRP-conjugated secondary antibody. In order to quantify 
the bound antibodies, TMB, a HRP substrate, was added to each well and sample 
absorbances were measured at a wavelength of 450 nm using a DTX 880 Multimode 
Detector (Beckman Coulter, Drea, CA). Additionally, cells were stained with Janus 
Green Whole-Cell Stain to determine cell number and sample absorbances were 
measured at a wavelength of 615 nm. p53 content per cell was calculated by dividing the 
absorbance measured at 450 nm with the absorbance measured at 615 nm.  
 
 
Figure 3.2. Schematic showing p53 assay protocol. Cells were treated with CTX-NO for 2 hours 
and then with TMZ or BCNU for 48 hours. After 48 hours, the cells were fixed and 
permeabilized. Samples were then incubated with p53-specific primary antibodies followed by 
HRP-conjugated secondary antibody. Next, TMB, an HRP substrate, was added to each well and 
sample absorbances were measured. 
 
3.2.7 Invasion Assay 
 An invasion assay was performed with T98G and U-87MG glioma cells using a 
Boyden chamber system consisting of a 6-well culture plate and 8-µm pore polyethylene 
terephthalate (PET) membrane inserts [9, 227]. The inserts were coated with type IV rat 
tail collagen (Olaf Pharmaceutical Inc, Worcester, MA), after which cells were seeded on 
the inserts at a density of 25,000 cells/cm2. After 24 hours, cells were exposed to CTX-
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NO (2 µM of NO) or the equivalent concentration of CTX. After 2 hours, the inserts were 
washed and serum-free media containing either TMZ or BCNU was added to the inserts. 
The inserts were then moved to a new 6-well culture plate containing fresh media. After 
48 hours of culture on the membranes, the cells were fixed in 4% formaldehyde and 
stained with 1% crystal violet in DI water (Fig. 3.3) [227, 228]. Cells on the upper side of 
the inserts were scraped off, and pictures of the cells on the underside of the filters were 
taken using a Nikon D90 digital camera attached to a Leica DM IL inverted contrasting 
microscope (Leica Microsystems, Inc., Bannockburn, IL). A minimum of three pictures 
were taken per insert.  
 
 
Figure 3.3. Schematic showing invasion assay protocol. 8-µm pore PET inserts were coated with 
collagen for 4 hours. T98G cells were then seeded on top chamber of the inserts. After 24 hours, 
cells were treated with CTX-NO for 2 hours and then with TMZ or BCNU for 48 hours. After 48 
hours, the cells were fixed and stained with 1% w/v crystal violet. Cells on the upper side of the 
inserts were scraped off and pictures of the cells on the underside of the filters were taken 
 
3.4.8 Statistical Analysis  
All experiments were carried out minimally in triplicate. Statistical comparisons 
were conducted using an ANOVA, with p-values less than 0.05 considered statistically 




3.5.1 CTX-NO pretreatment enhances the chemosensitivity of glioma cells  
Before quantifying the chemosensitizing effects of CTX-NO, control experiments 
were done to determine whether CTX (not reacted with NO) had any chemosensitizing 
effects. A two-hour pretreatment of glioma cells with CTX, resulted in no significant 
decrease in T98G or U-87MG chemoresistance (Fig 3.4). After establishing that CTX had 
no chemosensitizing effects, non-toxic concentrations of CTX-NO, BCNU and TMZ 
were identified, to test the ability of CTX-NO to induce chemosensitivity. Using non-
toxic doses of the therapeutics allowed any synergistic effects of the combined therapy to 
be easily observed.  
 
Figure 3.4. CTX (without reaction with NO) pretreatment does not affect the chemosensitivity of 
(A) T98G or (B) U-87MG cells. *p < 0.05, n = 3-5 for each experiment. 
 
Preliminary studies showed that BCNU concentrations as low as 75 µM and TMZ 
concentrations as low as 50 µM significantly decreased U-87MG cell viability, verifying 
that the U-87MG cell line (Fig. 3.5C and D) is significantly more chemosensitive than the 
T98G cell line (Fig. 3.5A and B) [229, 230]. Therefore, preliminary results from the cell 
viability studies of T98G cells, the more chemoresistant cell line, were used to determine 
non-toxic dosages. A range of 0-600 µM of BCNU was tested and no significant changes 
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in cell viability were measured at concentrations of 75 µM and 150 µM (Fig. 3.5A). 
Furthermore, 1-5 µM of NO added for 2 hours prior to addition of the chemotherapeutics 
resulted in an increase in BCNU efficacy. Similarly, when 0-800 µM of TMZ were tested 
for effects on cell viability, decreased T98G cell viability was measured at concentrations 
higher than 50 µM of TMZ (Fig. 3.5B). Based on these preliminary studies all further 
experiments were performed using a BCNU concentration of 75 µM, a TMZ 
concentration of 50 µM and NO concentration of 0-2 µM.  
 
Figure 3.5. CTX-NO pretreatment is able to increase the efficacy of both (A) BCNU and (B) 
TMZ in a dose dependent manner in T98G cells. Conversely U-87MG cell lines are significantly 
more chemosensitive and (C) BCNU and (D)TMZ significantly decrease cell viability at all tested 
concentrations. BCNU concentration of 75 µM, TMZ concentration of 50 µM and NO 
concentrations of 0-2 µM were chosen for further analysis based on results from T98G dosage 
curves. At these concentrations, the chemotherapeutics alone were not able to significantly reduce 








































































































Once concentrations of NO and the chemotherapeutics were identified, further 
experiments to determine the effects of the combined therapy on glioma and control cells 
were carried out. Upon exposure to chemotherapeutics, the viability of T98G cells 
remained mostly unchanged; remaining at 96.4 ± 5.0% and 101.1 ± 4.8% of the control 
following TMZ and BCNU treatment, respectively (Fig. 3.6A). NO treatment alone at 
these low concentrations also failed to significantly change T98G cell viability, with 1 
µM NO decreasing viability by less than 1% of the control and 2 µM NO decreasing cell 
survival to 94.9 ± 3.7% of the untreated control. NO pretreatment impacted T98G cell 
chemosensitivity towards TMZ and BCNU in a dose dependent manner. While exposure 
to 1 µM of NO released by CTX-NO for 2 hours prior to the TMZ treatment did not 
significantly reduce T98G cell viability (87.5 ± 7.2% of the control), doubling the NO 
dose to 2 µM of NO significantly decreased T98G cell viability to 76.8 ± 8.5% of the 
untreated control. BCNU treatment after NO delivery had an even more pronounced 
effect on cell viability. T98G cells exposed to 1 µM of NO had a cell viability of 82.9 ± 
7.8% of the control, and doubling the NO dose further decreased T98G cell viability to 
67.1 ±1.8% of the control (Fig. 3.6A).  
As expected, U-87MG cells were significantly more sensitive than T98Gs to the 
cytotoxic effects of both therapeutics, with viability reduced to 60.3 ± 2.4% and 39.8 ± 
1.9% of the control by TMZ and BCNU treatment, respectively (Fig. 3.6B). U-87MGs 
also displayed a higher sensitivity to NO; viability was reduced to 76.7 ± 3.2% and 63.0 
± 5.9% of the control by 1µM and 2 µM NO treatment, respectively. Cell viability levels 
of U-87MGs exposed to TMZ after the NO pretreatment were lowered to 45.1 ± 2.3% (1 
µM NO) and 34.8 ± 2.5% (2 µM NO) of the control; treatment with 1 µM NO and BCNU 
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also led to reduced viability (31.8 ± 0.5% of the control). However, the greatest reduction 
in glioma cell viability was observed when U-87MGs were exposed to 2 µM NO 
pretreatment followed by BCNU, resulting in a cell viability of 22.4 ± 1.8% of the 
untreated control. The targeted delivery of NO by CTX-NO resulted in no significant 
changes in the chemosensitivity of non-tumor control cells (NHAs shown in Fig. 3.6C 
and HBMECs shown in Fig. 3.6D).  
 
Figure 3.6. CTX-NO pretreatment is able to increase the efficacy of both chemotherapeutics on 
T98Gs (A) and of U-87MGs (B) cells without affecting NHA (C) and HBMEC (D) 
chemosensitivity. Glioma cell viability decreases in a dose dependant manner upon exposure to 
NO and U-87MG is more chemosensitive. Cells counted are presented as a percentage of the 
number of cells that received no treatment. *compared to no CTX-NO treatment 
(chemotherapeutic only), **p < 0.05 compared to treatment with only CTX-NO (1 µM), #p < 






3.5.2 CTX-NO pretreatment significantly reduces MGMT expression in glioma cells 
It has been widely reported that MGMT levels cannot be detected in U-87MG 
cells due to methylation of the enzyme and hence analysis of intracellular MGMT levels 
was assessed only in T98G glioma cells. The treatment of T98G cells with either TMZ or 
BCNU alone resulted in no significant changes in detected MGMT levels (Fig. 3.7). 
When T98G cells were treated with NO at concentrations of 1 µM or 2 µM, MGMT was 
decreased to 73.1 ± 5.9% and 60.1 ± 9.9% of the control, respectively. Equivalent 
concentrations of CTX (not reacted with NO gas) resulted no significant decrease in 
MGMT levels; however, the treatment of glioma cells with NO led to considerable 
decreases in detected MGMT. Exposure of T98Gs to both 1 µM NO and TMZ was able 
to decrease MGMT to 60.7 ± 15.2% of the untreated control, and increasing the NO to 2 
µM further reduced MGMT levels to 43.4 ± 13.2%. While treatment with 1 µM NO and 
BCNU only reduced MGMT levels to 83.6 ± 6.3% of the control, 2 µM NO followed by 
BCNU treatment resulted in a drastic reduction of MGMT levels to 34.6 ± 8.0% of the 
control value (Fig. 3.7)  
 
Figure 3.7. Levels of MGMT detected with treatment by CTX-NO alone and in conjugation with 
TMZ or BCNU treatment were significantly decreased in T98G cells. MGMT levels per total cell 
protein content are presented as a percentage of the untreated control (cell MGMT levels per cell 
protein content in cells receiving no treatment). #p < 0.05compared to treatment with only CTX-
NO, *p < 0.05, n = 3-5. 
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3.5.3 Combination treatment significantly reduces p53 expression in glioma cells 
Levels of intracellular p53 were also assessed, and neither chemotherapeutic had 
any effect on p53 levels in either cell type (Fig. 3.8). Though CTX-NO treatment was 
able to significantly decrease p53 expression in T98G cells in a dose dependent manner, 
with p53 levels decreased to 82.3 ± 11.4% and 79.8 ± 13.0% of the control at NO 
concentrations of 1 µM and 2 µM respectively (Fig. 3.8A), CTX-NO alone had no 
discernible effect on U-87MG glioma cells at either concentration of NO (Fig. 3.8B). The 
combination of TMZ and NO had little effect on p53 levels in T98G glioma cells, 
showing much the same trend as treatment with NO alone (81.5 ± 14.6% and 75.3 ± 
12.9% of the control level at 1 and 2 µM NO, respectively). On the other hand, treatment 
of T98Gs with both NO and BCNU led to much more significant decreases in detected 
p53 levels. In conjunction with BCNU, the lower concentration of NO reduced p53 
amounts to 73.1 ± 7.5% of the control, while 2 µM NO considerably decreased levels of 
p53 to 18.7 ± 7.0% of the untreated control. In U-87MGs the amounts of p53 did not vary 
significantly over most of the treatments, maintaining levels higher than 85% of the 
control, except at the combination of BCNU with 2 µM NO which reduced p53 levels to 




Figure 3.8. CTX-NO alone and in conjugation with TMZ or BCNU treatment stimulates a 
decrease in the p53 levels in T98G cells (A) in a dose dependant manner, while having little 
effect on U-87MG except with the combination of NO and BCNU (B). p53 expression per total 
cell number is presented as a percentage the untreated control value (p53 expression per total 
cells measured in cells receiving no treatment). *p <0.05, n = 3-5. 
 
3.5.4 CTX-NO treatment with chemotherapy significantly reduces glioma cell invasion 
Invasion assays were performed in transwell inserts coated with collagen to assess 
the effects of NO treatments on T98G human glioma cell invasion. After the 48 hour 
incubation period, cells which migrated through the collagen coating to the bottom of the 
insert were photographed (Fig. 3.9). As a result of significant decreases in cell death, 
effects of CTX-NO pretreatment on U-87MG could not be quantified. While it was 
visually observed that both the combination therapies, CTX-NO with BCNU and CTX-
NO with TMZ, inhibited the invasion of the T98G cells, in order to quantitatively 
compare the effects of the individual treatments, cells were counted using ImageJ 
software and a percentage reduction in invasion was calculated (Fig. 3.10). CTX and 
CTX-NO were able to decrease T98G cell invasion by 26.9 ± 13.1% and 29.3 ± 9.5%, 
respectively; however, BCNU and TMZ individually were unable to significantly reduce 
cell invasion. When CTX-NO treatment was coupled with chemotherapy, significant 
reduction in cell invasion was observed; the combination of NO and BCNU decreased 
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invasion by 70.5 ± 8.6% while NO in conjunction with BCNU decreased invasion by 




Figure 3.9. Inhibition of invasion of T98G cells through a collagen matrix was evident following 
the combination of NO pretreatment and chemotherapy. Photographs were taken of the bottom of 
collagen-coated transwell inserts showing invading T98G cells stained with crystal violet after the 




Figure 3.10. Percent decrease in transwell invasion of T98G cells resulting from the combination 
of NO treatment followed by TMZ or BCNU. The treatment of cells with CTX-NO combined 
with chemotherapeutics showed greater inhibition of glioma cell invasion than all other 



































NO has been shown to affect gliomas in a variety of ways, with research showing 
NO treatment results in the induction of apoptosis, radiosensatization and 
chemosensitization in tumor cells, and increased permeability of the BBB [143, 146, 
231]. Previous studies have used non-specific NO donors, including SNAP, GSNO, 
PABA/NO, DEA/NO and SPER/NO, to stimulate chemosensitivity in glioma cells [19, 
143, 146]. The non-specific nature of these NO donors requires that high doses of NO 
and thus, the donors themselves, be used for observable therapeutic benefit. This in turn 
may result in a variety of side effects. Herein, CTX-NO, a targeted NO donor, was 
studied for its ability to induce chemosensitivity selectively to glioma cells. A two hour 
incubation of glioma cells with CTX-NO prior to BCNU or TMZ treatment resulted in 
enhanced chemosensitivity in both T98G and U-87MG cell lines, whereas the 
chemosensitivity of the control cells, NHAs and HBMECs, was not affected. The 
selective effect of the NO pretreatment is a consequence of the targeted delivery of NO, 
as characterized in Chapter 2.  
To understand the mechanism of chemosensitivity, not only must the 
chemoprotective mechanisms of the cells be understood, but also the effects of TMZ and 
BCNU on tumor cells. Both TMZ and BCNU are alkylating agents that cause DNA 
damage by the alkylation of guanine residues and inter-strand crosslinking of DNA [15, 
161, 232]. MGMT restores DNA structure and function by transferring the methyl group 
from the oxygen in methylated guanine to a cysteine residue on MGMT [232]. Increased 
MGMT production in glioblastomas results in the heightened ability to repair the 
apoptosis-causing lesions and therefore, MGMT expression is often used as a predictor 
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for glioma response to chemotherapy [36, 233-235]. Studies have demonstrated the 
ability of MGMT inhibitors to induce chemosensitivity in tumor cells; however, their 
success in treating GBM has been limited because of systemic side effects and tumor cell 
resistance to the inhibitors [228].  
To determine the mechanism by which CTX-NO was able to enhance 
chemosensitivity in glioma cells, the consequences of NO exposure on MGMT 
expression was examined. Methylation of MGMT in U-87MG glioma cells results in low 
levels of MGMT in these cells and is therefore undetectable by Western blot analysis 
[230, 236-238]. Consequently, MGMT analysis after CTX-NO pretreatment was carried 
out only using T98G cells. CTX-NO exposure resulted in decreased MGMT levels, and 
this reduction was further enhanced when CTX-NO treatment was coupled with 
chemotherapy. These results suggest that one of the mechanisms by which NO enhances 
chemosensitivity in T98Gs is by decreasing the amount of functional MGMT, thus 
enhancing the efficacy of DNA alkylation. It has been shown that S-nitrosylation of the 
cysteine residue in the active site of MGMT causes the irreversible loss of DNA repair 
activity [239]. Additionally, the S-nitrosylation of MGMT has also been shown to quickly 
target the protein for degradation [239]. It is hypothesized that the reduction in MGMT 
expression observed after CTX-NO treatment is a consequence of the S-nitrosylation of 
MGMT. 
p53 has also been shown to play an integral role in numerous cytoprotective 
mechanisms. p53 not only limits the effect of chemotherapeutics, but also inhibits 
cytokine-induced NO production, thereby protecting glioma cells from the adverse 
effects of endogenously produced NO [124]. In fact, p53 is so effective in providing 
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glioma cells protection that studies have shown a positive correlation of p53 expression 
with glioma grade and proliferation indices [235, 240, 241]. Therefore, to further 
elucidate the mechanisms by which CTX-NO induced chemosensitivity in glioma cells, 
the effect of the targeted exogenous NO donor on p53 expression was examined. 
CTX-NO was able to decrease p53 expression in T98G cells alone, as well as 
when combined with chemotherapy. In U-87MG cells, p53 expression was significantly 
decreased only when the highest concentration of CTX-NO was combined with BCNU 
treatment. This is particularly intriguing because T98G cells express mutated p53, 
whereas U-87MG cells express wild-type p53 [242-244]. Mutations of p53 occur in 10% 
of primary glioblastomas and 65% of secondary glioblastomas [230]. Cells with 
mutations of p53 often demonstrate diminished ability to trigger apoptosis and enhanced 
DNA repair ability [223]. Furthermore, it has been shown that p53 mutant cell lines retain 
MGMT expression, whereas wildtype p53 cells are able to suppress MGMT reporter gene 
activity [241]. Thus, it is likely that presence of mutated p53 and the resulting retention 
MGMT expression are the causes for the less dramatic changes in viability seen in T98G 
cultures in comparison to U-87MG cells. 
Previous studies have also shown that NO can counter cytoplasmic sequestration 
of wild-type p53 and promote nuclear retention, leading to enhanced radiation-induced 
apoptosis in neuroblastoma [245]. Hence the results from the p53 assay suggest that wild-
type p53 is retained in the nucleus by exposure to CTX-NO, leading to increased 
apoptosis and a more noticeable impact on cell viability upon exposure to chemotherapy. 
Treatment with 2 µM NO in conjunction with BCNU leads to a drastic decrease in 
detected p53 in both T98G and U-87MG glioma cells. Though studies have suggested 
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that NO release can lead to the formation of an S-nitrosyl p53 that has impaired DNA-
binding ability and crosslinks upon NO release [246], this cannot explain the decrease in 
active p53 detected, especially since  this phenomenon is observed only in the presence 
of BCNU and the highest concentration of NO. Further studies investigating the effect of 
NO on the p53-mediated apoptosis pathway are required to further understand the role of 
NO in inducing chemosensitivity.   
Although CTX has been documented to inhibit glioma cell invasion [180, 210], 
the anti-invasive effect of CTX-NO, alone and in combination with chemotherapeutics is 
unknown, and hence was investigated. Using a Boyden chamber, T98G cells were seeded 
onto cell culture inserts coated with collagen IV and allowed to invade the matrix over 48 
hours, as described by Kenig and colleagues [9]. It was not possible to adequately track 
U-87MG invasion due to the drastic decrease in U-87MG cell viability in response to the 
treatments. Therefore, the invasion of only T98G cells could be studied. It was observed 
that CTX-NO pretreatment combined with TMZ or BCNU resulted in significant 
decreases in cell invasion, which were not observed when the cells were treated with only 
one drug. Thus, it is suggested that the combination of CTX-NO and chemotherapeuctics 
have a synergistic effect on the inhibition of glioma cell invasion. 
The studies discussed in this chapter demonstrate that CTX-NO is able to induce 
chemosensitivity in glioma cells by decreasing MGMT and mutant p53 expression. In 
addition to chemoresistance, another major hindrance to effective GBM treatment is the 
highly invasive nature of the glioma cells. This, combined with the anti-invasive effects 
observed in the Boyden chamber studies provided motivation to investigate, in an in-
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depth manner, the effect of CTX-NO on the invasion and migration of glioma cells. The 
findings of this study are presented in the next chapter.   
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CHAPTER 4: EFFECT OF TARGETED NO DELIVERY ON THE INVASIVE PROPERTIES OF 
GLIOMA CELLS 
 
4.1 Summary  
The highly invasive nature of GBM cells has proven to be a great challenge in the 
treatment the disease. Glioma cells are able to readily invade healthy brain tissue, making 
complete tumor resection impossible. Herein, an investigation into the effects of CTX-
NO, a targeted NO donor, on the invasive properties of glioma cells is presented. CTX 
has been reported to have significant anti-invasive effects in gliomas; however, the role 
of NO in tumor cell invasion is debated. The study presented herein sheds light on the 
role NO plays in the invasion of glioma cells and demonstrates that the anti-invasive 
properties of CTX are enhanced by conversion of CTX to CTX-NO. Using a Boyden 
chamber invasion assay and a modified scratch migration assay, it was observed that 
CTX-NO increased the ability of CTX to inhibit glioma cell invasion and migration. 
Further studies revealed that MMP-2 cell surface expression was reduced by both CTX-
NO and CTX, but MMP-9 expression was reduced only by CTX-NO. Additionally, the 




 A major obstacle to the successful treatment of GBM is the rapid and highly 
invasive growth of the tumor [9, 247-249]. The glioma microenvironment is 
characterized by one large localized aggregation of tumor cells and numerous smaller 
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populations distant from the main tumor mass [250]. Although systemic spread is rare, 
infiltration of the brain parenchyma by glioma cells results in the recurrence of the tumor 
[153, 190, 250, 251]. Invasion of normal tissue by tumor cells is a multi-step process but 
one major step in the process is the degradation of the ECM [26, 185].  
MMP-2, also referred to as gelatinase A, a 72-kilodalton enzyme, has the ability 
to degrade collagen type IV, an important component of the brain ECM. Consequently, 
cells expressing MMP-2 are able to degrade ECM and invade surrounding tissue [8, 252]. 
As mentioned in Chapter 2, CTX is able to target glioma cells by binding to cell surface-
bound MMP-2, which is overexpressed in glioma cells but is not expressed in normal 
glial cells and neurons. On binding to MMP-2, CTX has dual effects, not only inhibiting 
enzymatic activity, but also reducing MMP-2 surface expression [180]. As a 
consequence, the chloride channel that is part of the MMP-2 complex is also internalized 
[253]. This reduction in chloride channels decreases the outward directed chloride 
gradient, which in turn inhibits the cell volume shrinkage required for cell invasion [254]. 
These effects cumulatively result in an inhibition of glioma cell invasion as a result of 
CTX exposure.  
In addition to MMP-2, MMP-9, referred to as gelatinase B, has been shown to 
also have a prominent role in glioma invasion [10, 255]. Expression of MMP-9, which is 
significantly higher in gliomas compared to normal brain tissue, directly correlates with 
the malignancy grade of the glioma [10, 256-258]. Furthermore, studies have shown that 
suppression of MMP-9 in mice not only results in an inhibition of glioma migration and 
invasion, but also in the prevention of intracranial tumor growth following tumor cell 
injection [259-261]. The role of NO in tumor invasion is ambiguous and therefore to 
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clarify the role of this biomolecules on glioma invasion, the anti-glioma effects of a 
targeted NO donor, CTX-NO, were investigated in this study. 
   
4.3 Objective 
In this chapter, a study of the differences in the effect of CTX and CTX-NO 
treatments on glioma cell invasion and migration is presented. CTX-NO and CTX were 
assessed for their effect on: 
 Glioma cell invasion 
 Glioma cell migration 
 MMP-2 and MMP-9 surface expression 
 MMP-2 and MMP-9 activity 
 
4.4 Methods and Materials 
4.4.1 Chemicals 
Minimum Essential Media (MEM), fetal bovine serum (FBS), L-glutamine-
penicillin-streptomycin (GPS), trypsin-EDTA and non-essential amino acids were 
obtained from Mediatech, Inc. (Manassas, VA). NO gas was obtained from Airgas 
(Atlanta, GA), chlorotoxin (CTX, purity > 87%) was obtained from Bachem Chemicals 
(Torrance, CA). Matrigel and transwell inserts was purchased from BD Biosciences 
(Bedford, MA). Unless otherwise mentioned, all other chemicals were obtained from 




4.4.2 Cell maintenance 
T98G and U-87MG human glioblastoma cells (American Type Cell Culture, 
Manassas, VA), were cultured in MEM with 10% FBS, 1% GPS and 1% non-essential 
amino acids at 37oC and 5% CO2. Cell passages 5-12 were used.  
 
4.4.3 NO donor synthesis  
CTX-NO was synthesized as described in section 2.4.3. As before reacted 
samples were freeze dried and stored at -20oC until used. At the time of experiments 
CTX-NO samples were dissolved in DI to form solutions such that cells were exposed to 
the desired concentration of NO.  
 
4.4.4 Viability studies 
T98G and U-87MG cells were seeded in 96-well plates at a density of 25,000 
cells/cm2. After allowing cells to adhere for 24 hours, the cells were incubated for 48 
hours with 0-145 nM of CTX-NO (0-2 µM of NO) or CTX. After 48 hours, the cultures 
were rinsed thoroughly to remove dead cells; the remaining adherent cells were removed 
from the culture surface using trypsin-EDTA and counted using a Beckman z1 Particle 
Counter (Beckman Coulter, Drea, CA). Viability was calculated as described in section 
2.4.6 
 
4.4.5 Invasion assay 
An invasion assay was performed using a Boyden chamber system consisting of a 
24-well culture plate and 8-µm pore polyethylene terephthalate (PET) membrane inserts 
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(Fig 4.1). The inserts were coated with Matrigel (0.25mg/ml) in 0.01 M Tris (pH 8.0) 
containing 0.7% sodium chloride and incubated at 37oC for 4 hours, after which cells 
were seeded on the inserts at a density of 37,500 cells/cm2. After 24 hours, cells were 
incubated with serum-free media containing 0-145 µM of CTX-NO or CTX. The lower 
portion of the boyden chamber was filled with media containing 10% FBS, thereby using 
serum as a chemotactic factor to induce cells to invade the Matrigel coating. After 48 
hours of culture, the cells on the underside of the inserts were fixed in 4% formaldehyde 
and stained with 1% w/v crystal violet in DI. Cells on the upper side of the inserts were 
scraped off, and pictures of the cells on the underside of the filters were taken using a 
Nikon D90 digital camera attached to a Leica DM IL inverted contrasting microscope 
(Leica Microsystems, Inc., Bannockburn, IL). A minimum of three pictures were taken 




Figure 4.1. Schematic representation of the invasion assay.  24-well cell culture inserts with an 8 
μm pore size PET membrane, were uniformly coated with Matrigel matrix for 4 hours. Glioma 
cells were seeded on the upper compartment, and after 24 hours incubated with CTX or CTX-NO 
in serum-free media. Media containing 10% FBS was placed in the lower chamber. After 48 hour 
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4.4.6 Migration assay 
To assess the effect of CTX-NO on cell migration, the Oris™ 96-well cell 
migration assay kit (Platypus Technologies, Madison, WI) was used according to the 
manufacturer's instructions (Fig 4.2). In brief, 4 × 104 T98G cells were seeded in each 
well. After 24 hours, the stopper was removed and cells were incubated with media 
containing 0-145 nM CTX or CTX-NO. The cells were then allowed to migrate into the 
detection zone. After 48 hours the cells were fixed with 4% formaldehyde and stained 
with 1% w/v crystal violet in DI. Pictures of the cells invading the detection zone were 
taken using a Nikon D90 digital camera attached to a Leica DM IL inverted contrasting 
microscope (Leica Microsystems, Inc., Bannockburn, IL). Migration was calculated by 





Figure 4.2. Schematic representation of the Oris™ migration assay. Stoppers were placed in the 
center of 96-well plates and glioma cells were seeded. After 24 hours the stoppers were removed 
to expose the detection zone. Cells were incubated with CTX or CTX-NO and allowed to migrate 
into the detection zone. After 48 hours the cells were fixed and stained. 
   
U-87MG cell migration was quantified using the same assay, albeit some 
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each well. After 24 hours, the stopper was removed and cells were incubated with media 
containing 0-72 nM CTX or CTX-NO. Higher concentrations of CTX-NO resulted in 
significant cell death and that is why U-87MG migration assays were performed using 
the aforementioned CTX-NO concentration range. The cells were allowed to migrate into 
the detection zone and migration was quantified after 24 and 48 hours. At the end of the 
incubation period, the cells were fixed, stained and photographed as previously described.  
 
4.4.7 MMP-2 and MMP-9 immunocytochemistry studies 
T98G and U-87MG cells were seeded in black walled 96-well plates at a density 
of 25,000 cells/cm2. As before, after 24 hours the cells were treated with CTX-NO or 
CTX for 48 hours. After 48 hours, the cells were fixed with 4% formaldehyde and stained 
for either MMP-2 or MMP-9 surface expression (Fig. 4.3). In brief, formaldehyde was 
removed from wells and cells were then washed with PBS and incubated at room 
temperature for 1 hour with 5% BSA in PBS, which served as a blocking agent for 
nonspecific binding. Antibodies to MMP-2 (Abcam, Cambridge, MA), or MMP-9 
(Abcam, Cambridge, MA) at a dilution of 1:200 in 1% BSA solution, were incubated 
with glioma cells overnight at 4oC. Cells were then washed and incubated in the dark for 
2 hours with fluorescein-conjugated anti-rabbit IgG secondary antibody (Rockland 
Immunochemical, Gilbertsville, PA) at a dilution of 1:500 in 1% BSA solution. After 2 
hours, the cells were washed with PBS and fluorescence was assessed using a Leica DMI 
4000B fluorescent microscope equipped with a Hamamatsu ORCA-ER digital camera 
(Leica Microsystems, Inc., Bannockburn, IL). A minimum of three pictures were taken 






Figure 4.3. Schematic of the MMP surface expression assay. Cells were treated with CTX-NO or 
CTX for 48 hours. At the end of the incubation period were fixed with 4% formaldehyde and 
blocked with BSA. The cells were then incubated overnight with primary antibodies specific for 
MMP-2 or MMP-9. The next day, cells were incubated for 2 hours with FITC labeled secondary 
antibodies. Fluorescence microscopy was then used to assess the surface expression of the MMP-
2 or MMP-9. 
 
4.4.8 MMP-2 and MMP-9 activity assay   
While the immunocytochemistry studies were able to quantify the surface 
expression of MMP-2 and MMP-9, it is the activated forms of the enzymes that are 
secreted and degrade the ECM. It was therefore necessary to quantify the effect of CTX 
and CTX-NO on secreted MMPs. T98G and U-87MG cells were seeded in 96-well plates 
at a density of 25,000 cells/cm2. As before, after 24 hours the cells were treated with 
CTX or CTX-NO for 48 hours. At the end of the incubation period, the media was 
collected and centrifuged at 10,000 x g for 10 minutes. The supernatant was mixed 50:50 
with 100 µM of a quenched fluorogenic substrate specific for MMP-2 and MMP-9 (DNP-
Pro-Leu-Gly-Met-Trp-Ser-Arg-OH; EMD Millipore Billerica, MA) in black walled 96-
well plates [262]. The mixtures were incubated for 20 minutes at room temperature with 
gentle agitation. The fluorescent signal at an excitation wavelength of 280 nm and an 
NO NO
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emission wavelength of 360 nm was monitored at room temperature on a Synergy H4 
Multi-Mode Plate Reader (Biotek, Winooski, VT) to measure enzymatic activity.  
 
4.4.8 DQ-collagen assay   
Glass coverslips were coated with Matrigel containing with 100 µg/ml DQ-
collagen IV (Invitrogen, Carlsbad, CA ) for 15 min at 37°C [263, 264]. T98G or U-87MG 
cells were plated at a density of 25,000 cells/cm2. As in previous experiments, cells were 
allowed to adhere for 24 hours and then incubated with 36 nM of CTX or CTX-NO for 
48 hours. At the end of 48 hours, cells were incubated with 5µg/ml of orange plasma 
membrane stain (Invitrogen, Carlsbad, CA) for 5 minutes at 37oC. Fluorescent 
degradation products from the DQ-collagen were then imaged using a Zeiss LSM 510 
UV Confocal Microscope (Carl Zeiss Inc, Peasbody, MA) with the appropriate filters.  
 
4.5 Results  
4.5.1 Viability studies 
To ensure that changes in migration and invasion were not due to cell death, viability 
studies were performed in which T98G and U-87MG cells were exposed for 48 hours to 
0-145 nM of CTX-NO (0-2 µM of NO) as well as 0-145 nM of CTX. T98G cell viability 
was not significantly affected at these concentrations, and three concentrations, 36, 72 
and 145 nM, of CTX-NO were identified for further experiments. At these concentrations 
T98G viability was measured to be 100.0 ± 2.4%, 100.2 ± 6.6% and 93.4 ± 2.5% of the 






Figure 4.4. Effect of low doses of CTX and CTX-NO on the cell viability assay of (A) T98G and 
(B) U-87MG cells. The non-cytotoxic range for T98Gs was identified as 0-145 nM of CTX-NO; 
whereas the concentration range for further experiments with U-87MGs was identified as 0-72 
nM of CTX-NO. *p < 0.05, #p < 0.05 compared to DI, n = 3-5.  
 
As observed in earlier chapters, U-87MG cells were more sensitive to NO 
treatment. U-87MG cells incubated with 145 nM of CTX-NO had reduced cell viability 
of 66.4 ± 6.9%. Therefore the concentration range for further experiments with U-87MG 
cells was reduced to 0-72 nM of CTX-NO. U-87MG cell viability was measured as 99.7 
± 6.0% at a CTX-NO concentration of 18 nM; 96.4 ± 4.4% at a CTX-NO concentration 
of 36 nM and 87.6 ± 6.3% of the control at a CTX-NO concentration of 72 nM (Fig 
4.4B). CTX, at all tested concentrations, was innocuous and did not affect U-87MG cell 
viability (Fig 4.4B) 
 
4.5.2 CTX-NO enhances ability of CTX to inhibit glioma cell invasion  
Invasion assays were performed in transwell inserts coated with Matrigel to assess 
the differences in the effects of CTX and CTX-NO treatments on glioma cell invasion. 
After the 48 hour incubation period, T98MG (Fig. 4.5A) and U-87MG (Fig. 4.6A) cells 
that were initially seeded on top of the insert and had migrated through the Matrigel 
coating to the bottom of the insert were photographed. In order to quantify the effects of 
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the individual treatments, cells were counted using ImageJ software and the percent of 
invading cells was calculated.  
 
 
Figure 4.5. Invasion assay with T98G cells. (A) Pictures showing the invasion through a matrigel 
matrix of T98G cells incubated for 48 hours with 0-145 nM of CTX (upper row) or CTX-NO 
(lower row). Pictures were taken of the bottom of Matrigel-coated transwell inserts showing 
invading T98G cells stained with crystal violet after the indicated treatment. Scale bar = 20 µm. 
(B) Quantification of the cell invasion using ImageJ software shows that both CTX and CTX-NO 
inhibit T98G cell invasion and CTX-NO enhances the anti-invasive properties of CTX. *p < 0.05, 
#p < 0.05 compared to DI water, n = 7.  
 
CTX was able to decrease T98G cell invasion in a dose dependent manner and 
CTX-NO enhanced this inhibition. At a concentration of 36 nM invasion was reduced to 
85.9 ± 7.6% of the control by CTX, and CTX-NO at the same concentration reduced 
invasion to 74.8 ± 4.9% (Fig 4.5B). This same phenomenon was observed at higher 
concentrations, with CTX at a concentration of 72 nM reducing T98G cell invasion to 
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78.1 ± 3.6%, while CTX-NO at the same concentration reduced invasion to 67.1 ± 3.8% 
of the control. At the highest concentration tested, 145 nM, invasion was reduced to 69.1 
± 3.0% and 55.5 ± 6.5% of the control, by CTX and CTX-NO, respectively (Fig 4.5B). 
 
Figure 4.6. Invasion assay with U-87MG cells. (A) Pictures showing the invasion through a 
matrigel matrix of U-87MG cells incubated for 48 hours with 0-72 nM of CTX (upper row) or 
CTX-NO (lower row). Pictures were taken of the bottom of matrigel-coated transwell inserts 
showing invading U-87MG cells stained with crystal violet after the indicated treatment. Scale 
bar = 20 µm. (B) Quantification of the cell invasion using ImageJ software shows that, as 
observed in T98G cells, both CTX and CTX-NO inhibit U-87MG invasion in a dose dependent 
manner and CTX-NO enhances the anti-invasive properties of CTX. *p < 0.05, #p < 0.05 
compared to DI water, n = 7.  
 
Similar to the effects seen in T98G cells, CTX-NO enhanced the dose dependent 
attenuation of glioma cell invasion elicited by CTX. At the lowest concentration, 18 nM, 
U-87MG invasion was reduced to 85.2 ± 11.1% and 74.2 ± 8.5% of the control by CTX 
and CTX-NO, respectively (Fig. 4.6B). U-87MG invasion was reduced to 72.7 ± 2.9%  
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and 67.1 ± 4.7% by CTX at concentrations of 36 nM and 72 nM, respectively. At the 
same concentrations, CTX-NO reduced U-87MG invasion to 58.8 ± 6.5% and 47.0 ± 
8.7% of the control (Fig. 4.6B).  
 
4.5.3 CTX-NO enhances ability of CTX to inhibit glioma cell migration  
In addition to the invasion assay, a modified scratch assay was performed to 
compare the effects of CTX and CTX-NO on glioma cell migration. In T98G cells 
exposed to 36 nM of CTX, migration was reduced to 88.9 ± 9.1% of the control, whereas 
the same concentration of CTX-NO reduced cell migration to 77.5 ± 7.8%. The enhanced 
effect of CTX-NO on T98G migration was more pronounced at higher concentrations. In 
T98G cells exposed to 72 nM of CTX-NO, migration was reduced to 72.6 ± 3.6% of the 
control, whereas the same concentration of CTX reduced cell migration to 86.9 ± 9.2%. 
The greatest difference in glioma cell migration was observed at a concentration of 145 
nM, at which CTX was able to limit migration to 78.5 ± 7.2% and CTX-NO limited 






Figure 4.7. OrisTM Migration assay with T98G cells (A) Pictures showing the migration of T98G 
cells, incubated for 48 hours with 0-145 nM of CTX (upper row) or CTX-NO (lower row). Scale 
bar = 500 µm. (B) Quantification of cell migration using ImageJ software shows that both CTX 
and CTX-NO inhibit T98G cell migration in dose dependent manner. CTX-NO enhances the anti-
migration effects of CTX. *p < 0.05, #p < 0.05 compared to DI water, n=4. 
  
U-87MG cells have a different morphology than T98G cells and therefore did not 
form a uniform monolayer around the stopper. The morphology of these cells made 
quantifying cell migration challenging. When the migration assay was performed for 48 
hours, as done with the T98G cells, the U-87MG cells migrated to cover the detection 
zone in all conditions (Fig. 4.8A). At the two lower concentrations of CTX, 18 nM and 
36 nM, no significant decreases in U-87MG cell migration was observed. At 72 nM, the 
highest concentration of CTX, migration was reduced to 89.6 ± 2.3% of the control. 
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CTX-NO reduced migration to 90.7 ± 2.0% and 86.0 ± 9.9% of the control at 
concentrations of 36 nM and 72 nM, respectively (Fig. 4.8B). The reductions at both 
these concentrations, although statistically significant from the control, were not 
statistically different from the reductions observed after incubation with the same 
concentrations of CTX (Fig. 4.8B).  
 
Figure 4.8. OrisTM Migration assay with U-87MG cells (A) Pictures showing the migration of 
U-87MG cells, incubated for 48 hours with 0-72 nM of CTX (upper row) or CTX-NO (lower 
row). Scale bar = 500 µm. (B) Quantification of the cell migration after 48 hours using ImageJ 
software. No differences between the effects of CTX and CTX-NO were observed. *p < 0.05, #p 





Figure 4.9. OrisTM Migration assay with U-87MG cells over 24 hours. (A) Pictures showing the 
migration of U-87MG cells, incubated for 24 hours with 0-72 nM of CTX (upper row) or CTX-
NO (lower row). Scale bar = 500 µm. (B) Quantification of the cell migration after 48 hours using 
ImageJ software. CTX-NO attenuated U-87MG migration at all concentrations, whereas CTX 
decreased glioma cell migration only at the highest concentrations. *p < 0.05, #p < 0.05 
compared to DI water, n=4. 
 
In an alternate experiment with U-87MG cells the migration assay was performed 
only for 24 hours, instead of 48 hours. In this shortened incubation period, inhibition of 
U-87MG migration was observed after exposure to both CTX and CTX-NO (Fig 4.9A). 
After a 24 hour exposure to 18 nM of CTX, U-87MG migration was decreased to 92.6 ± 
5.9% of the control, whereas at the same concentration of CTX-NO, U-87MG migration 
was decreased to 77.0 ±12.9% of the control (Fig. 4.9B). Similarly, migration of U-
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87MG cells exposed to 72 nM of CTX was decreased to 61.4 ±4.5%, while migration of 
cells exposed to the same concentration of CTX-NO was reduced to 52.7 ± 7.6 % of the 
control (Fig. 4.9B). 
 
4.5.4 CTX and CTX-NO decreased MMP-2 surface expression in a dose dependent 
manner  
Although it is well documented that CTX binds to MMP-2 on glioma cell surfaces 
and consequently decreases MMP-2 surface expression, the effect of CTX-NO on MMP-
2 surface expression also needed to be investigated. In T98G cells exposed to 36 nM of 
CTX, MMP-2 expression was decreased to 69.5 ± 7.5% of the control (Fig. 4.10A). 
MMP-2 expression in T98G cells was reduced to 56.2 ± 5.6% of the control after 
exposure to 145 nM of CTX, which was the highest concentration of CTX tested. At the 
two lower concentrations of CTX-NO, 36 nM and 72 nM, although MMP-2 was 
decreased to 62.5 ± 6.2% and 52.2 ± 5.6% of the control, respectively, these reductions 
were not significantly different from those observed at the corresponding concentrations 
of CTX. When T98G cells were exposed to 145 nM of CTX-NO, MMP-2 surface 
expression was measured to be 47.4 ± 0.9% of the control, which was significantly 
different to the decrease observed when T98G cells were exposed to the corresponding 
concentration of CTX (Fig. 4.10A).  
As observed in T98G cells, when U-87MG cells were exposed to CTX or CTX-
NO, MMP-2 surface expression was decreased in a dose dependent manner (Fig 4.10B). 
MMP-2 expression in U-87MG cells was decreased to 72.4 ± 9.6% and 69.8 ± 4.3% of 
the control after they were exposed to 18 nM of CTX and CTX-NO respectively. At 
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higher CTX and CTX-NO concentrations, more pronounced differences in the effects of 
the two biomolecules were observed. MMP-2 expression in U-87MG cells, after 
incubation with 36 nM of CTX, was decreased to 51.9 ± 2.6% of the control, whereas 
exposure to the corresponding CTX-NO concentration resulted in MMP-2 expression 
reduced to 35.3 ± 8.7% of the control. The lowest MMP-2 expression in U-87MG cells, 
27.5 ± 8.7% of the control, was observed after the cells were exposed to 72 nM CTX-NO 
(Fig 4.10B). Exposure to the corresponding concentration of CTX decreased MMP-2 
expression to 49.5 ± 6.4% of the control.  
 
 
Figure 4.10. MMP-2 surface expression in (A) T98Gs and (B) U-87MGs after incubation with 
CTX or CTX-NO for 48 hours. Both CTX and CTX-NO decreased MMP-2 expression but it was 
only at the highest concentrations that CTX-NO enhanced the effect of CTX in decreasing MMP-
2. *p < 0.05, #p < 0.05 compared to DI water, n = 3-5. 
 
4.5.5 MMP-9 expression reduced only by CTX-NO 
MMP-9 surface expression in T98G cells was not significantly reduced by CTX 
and was measured to be 98.0 ± 10.9% of the control after the cells were exposed to 145 
nM of CTX, the highest concentration of CTX tested (Fig. 4.11A). At a concentration of 
36 nM CTX-NO, MMP-9 surface expression in T98G cells was reduced to 89.9 ± 9.4% 
of the control. This decrease, however, was statistically insignificant from the control. At 
higher concentrations of CTX-NO, 72 nM and 145 nM, MMP-9 surface expression in 
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T98G cells was reduced to 85.8 ± 9.5% and 84.9 ± 6.0% of the control, respectively (Fig. 
4.11A).  
Similarly, no significant decreases in MMP-9 expression were observed when U-
87MG cells were incubated with CTX. At the highest concentration of CTX tested, 
MMP-9 expression was 100.6 ± 10.8% (Fig. 4.11B). On the other hand, MMP-9 
expression in U-87MG cells was reduced in a dose dependent manner by CTX-NO. At 
the lowest concentration of CTX-NO, 18 nM, MMP-9 expression was reduced to 80.6 ± 
13.8% of the control. The most pronounced decrease in MMP-9 expression to 55.9 ± 
15.6% was observed after U-87MG cells were exposed to 72 nM of CTX-NO (Fig. 
4.11B). 
 
Figure 4.11. MMP-9 surface expression in (A) T98Gs and (B) U-87MGs after incubation with 
CTX or CTX-NO for 48 hours. CTX did not decrease MMP-9 expression at any of the tested 
concentrations, whereas CTX-NO decreased MMP-9 significantly. *p < 0.05, #p < 0.05 
compared to DI water, n = 5-8. 
 
4.5.6 CTX induced decrease of MMP-2 and MMP-9 activity accentuated by CTX-NO 
In order to measure the activity of MMP-2 and MMP-9, conditioned media from 
cell cultures exposed to CTX or CTX-NO was incubated with an MMP-2 and MMP-9 
specific fluorogenic substrate. Conditioned media collected from T98G cells exposed to 
CTX, showed a modest decrease in enzyme activity, but exposure to CTX-NO resulted in 
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a more pronounced decrease in enzymatic activity (Fig. 4.12A). After a 48-hour 
incubation with 36 nM CTX, MMP-2 and MMP-9 activity was decreased to 92.5 ± 
4.39% of the control. Incubation with 36 nM CTX-NO showed a greater decrease in 
enzyme activity, measured as 83.3 ± 1.4% of the control (Fig. 4.12A). Exposure to 72 nM 
of CTX-NO decreased enzymatic activity to 76.7 ± 1.4% of the control, whereas 
exposure to the same concentration of CTX only reduced the activity to 95.0 ± 0.4% (Fig. 
4.12A). At the highest concentration of CTX-NO, 145 nM, enzymatic activity was 
reduced to 66.4 ± 2.2% of the control, whereas the same concentration of CTX reduced 
enzymatic activity to 93.5 ± 1.8%.  
Figure 4.12: MMP2/MMP-9 activity of (A) T98Gs and (B) U-87MGs. CTX-NO enhances the 
inhibitory effect of CTX on the activity of MMP-2 and MMP-9 in a dose dependent manner. *p < 
0.05, #p < 0.05 compared to DI water, n=3-6. 
 
MMP-2 and MMP-9 enzymatic activity in U-87MG cells was decreased by both 
CTX and CTX-NO in a dose dependent manner. At the lowest concentration of CTX and 
CTX-NO, enzymatic activity in U-87MG cells was decreased to 91.3 ± 3.5% and 84.1 ± 
2.6% of the control, respectively. At a higher concentration, 36 nM, CTX-NO decreased 
enzyme activity in U-87MG cells to 79.6 ± 1.9% of the control and CTX reduced activity 
to 89.2 ± 3.1% of the control. At the highest concentration of CTX and CTX-NO, 72 nM, 
the greatest decreases in enzymatic activity in U-87MG cells were observed. At this 
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concentration, CTX and CTX-NO decreased enzymatic activity to 88.3 ± 1.7% and 73.0 
± 2.6% of the control, respectively (Fig. 4.12A).   
 
4.5.7 DQ-collagen assay 
In order to visually assess the effect of CTX and CTX-NO treatment on the 
proteolytic activity of MMPs, cells grown on a mixture of matrigel and DQ-collagen 
were treated with CTX or CTX-NO. Activated collagenases, including MMP-2 and 
MMP-9, resulted in the release of fluorogenic degradation products from DQ-collagen, 
which were imaged using confocal microscopy. Images of T98G cells showed that the 
cells grew in clusters, and cells treated with DI, CTX and CTX-NO, all showed 
pericellular degradation of the DQ-collagen (Fig, 4.13). Nonetheless, a difference in the 
pattern of the fluorescence was observed in the cells treated with CTX-NO. After 
treatment with CTX-NO, the fluorescence was concentrated towards the center of the 
cluster whereas for the other conditions fluorescence was observed on the periphery of 




Figure 4.13. Confocal images of T98G cells gown on Matrigel/DQ-collagen mixture and exposed 
to DI water (top row), 36 nM of CTX (middle row) and 36 nM of CTX-NO (bottom row) for 48 
hours. Secretion of MMPs from the cells results in the degradation of DQ-collagen and the 
subsequent release of fluorescence (middle column). Pictures show pericellular release of MMPs. 
Scale bar = 50 µm 
 
Images of U-87 cells showed, that in contrast to the clusters observed in T98G 
cells, these cells grew in a more diffuse manner (Fig. 4.14). However, similar to the 
observations in T98G cells, pericellular degradation of DQ-collagen was observed. 
However, in contrast to the T98G cells, when U-87MG cells were incubated with CTX-
NO, green fluorescence was also observed within the cell, indicating intracellular 
expression of MMPs. This suggests that CTX-NO maybe inhibiting the secretion of 




Figure 4.14. Confocal pictures of U-87MG cells gown on Matrigel/DQ-collagen mixture and 
exposed to DI water (top row), 36 nM of CTX (middle row) and 36 nM of CTX-NO (bottom 
row) for 48 hours. Secretion of MMPs from the cells results in the degradation of DQ-collagen 
and the subsequent release of fluorescence (middle column). Pictures show pericellular release of 
MMPs. Scale bar = 50 µm 
 
4.6 Discussion 
Glioma invasion is a significant challenge in successful treatment of the disease, 
even though gliomas are the only cancers to grow in a confined space [253]. Gliomas 
initially invade the fluid-filled space in the cranium, which corresponds to about 15% of 
the cranial space [253]. However, when this space becomes insufficient for further tumor 
growth, the glioma cells invade the peritumoral region by degrading the ECM of 
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surrounding brain tissue [31]. Increased expression of ECM degrading enzymes, 
including MMPs, has been observed in highly invasive gliomas.  
CTX, a protein extracted from scorpion venom, has been extensively studied, not 
only because of its ability to target glioma cells but because of its anti-invasive properties 
[180, 187, 210, 265]. Although CTX has well-documented anti-invasive properties, the 
role of NO in tumor cell invasion is debated. Some studies have indicated that NO aids in 
tumor invasion [153, 156, 157, 266], whereas other work suggests the opposite [267, 
268]. Hence, after the characterization of the glioma-targeting NO donor, CTX-NO, it 
was imperative to study the effect of the transformation of CTX into an NO donor on the 
anti-invasive properties of the former protein.  
Boyden chamber invasion assays confirmed that CTX does indeed inhibit glioma 
invasion. It was also observed that CTX-NO enhanced the ability of CTX to decrease 
glioma cell invasion in both T98G and U-87MG cells to less than 70% of the control. 
Migration studies of T98G cells reflected the same pattern observed in the invasion 
studies. CTX inhibited T98G migration by approximately 20%, but CTX-NO decreased 
T98G migration by over 50%. The migration studies of U-87MG cells did not result in 
observations of significant inhibition of migration and only at the highest concentration 
of CTX-NO was U-87MG migration reduced by 10%. The lack of response of U-87MG 
is partially attributed to the inability of the cells to form a uniform monolayer in 2D 
culture, thus making quantifying migration challenging. As an alternative, CTX and 
CTX-NO incubation times were reduced to 24 hours for the U-87MG migration studies. 
This reduction prevented the U-87MG cells from completely covering the detection zone 
allowed better measurement of migration. In this shortened experiment, it was observed 
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that CTX-NO inhibited migration to under 55% of the control, whereas migration 
remained above 60% when U-87MG cells were incubated with CTX. These studies 
demonstrated that low doses of NO (up to 2 µM) released from CTX-NO have anti-
invasive properties. These results are in agreement with previous studies, which have 
shown NO donors are able to inhibit tumor cell invasion [145, 268, 269].  
Localization of MMP-2 and MMP-9, along with other proteinases, on the cell 
surface in response to various integrins is an important step in cell invasion and migration 
[270-272]. Thus, in order to elucidate the mechanism by which NO enhanced the ability 
of CTX to attenuate glioma invasion, the effects of these treatments on MMP-2 and 
MMP-9 cell surface expression were studied using immunocytochemistry. CTX is known 
to bind to MMP-2 and consequently results in the internalization of the complex; 
therefore, as expected, CTX was able to decrease MMP-2 expression to less that 55% of 
the control in both T98G and U-87MG cells. At lower concentrations of CTX-NO 
comparable decreases in MMP-2 expression were observed. However, a statistically 
greater decrease in MMP-2 expression was observed at the highest concentration of 
CTX-NO treatment compared to CTX treatment. Conversely, although CTX treatment 
did not decrease MMP-9 surface expression, CTX-NO treatment resulted in MMP-9 
reductions in a dose dependant manner. This observation is in agreement with previous 
studies using endothelial cells, which have shown that NO activated transcription factor 3 
(ATF3), which in turn inhibited MMP-2 mRNA expression [273]. Although significant 
differences in the surface expression of MMP-2 in cells treated with CTX and CTX-NO 
were not observed, differences in MMP-9 expression were observed and the activation of 
ATF3 may be a possible mechanism for this observation.  
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 While localization of MMPs to the cell surface is a valuable indicator of the 
invasive properties of glioma cells, activation of MMPs is essential for the degradation of 
the ECM by these enzymes [29, 255, 257]. Therefore, in order to determine the effect of 
CTX and CTX-NO on the proteolytic activity of MMP-2 and MMP-9, conditioned media 
was incubated with a fluorogenic substrate for these enzymes. Results from this 
experiment showed that while CTX incubation resulted in a decrease of approximately 
15% of the enzymatic activity, incubation with CTX-NO, at the highest concentration, 
resulted in over 25% reduction in enzymatic activity. Although the aforementioned 
substrate has been optimized for MMP‐2 and MMP‐9, it may also be cleaved by other 
classes of MMPs [262]. Nonetheless, it can be inferred that in comparison to CTX, MMP 
activity is indeed decreased to a greater extent by CTX-NO. The reduction in enzymatic 
activity may be a direct consequence of the reduction of MMP surface expression or the 
NO could be decreasing the enzymatic activity of each MMP molecule. MMPs are 
activated by a cysteine switch, which results in the active zinc site being exposed [274]. 
S-nitrosylation of cysteine thiols on proteins has been shown to result in decreased 
enzymatic activity [129, 274-276]. Thus, it is proposed that one of the reasons for the 
decreased MMP-2 and MMP-9 activity observed after CTX-NO treatment is S-
nitrosylation of cysteine residues, which in turn prevents the exposure of the active site. 
Interestingly, S-nitrosylation of MMP-9 has also been implicated as a mechanism by 
which the enzyme is activated [277]. As discussed previously, the effect of NO varies 
depending on cell type, duration of exposure, and origin [126, 278], and it is proposed 
that whereas endogenous NO may lead to activation of MMPs, exogenous NO can 
potentially have inhibitory effects on MMP activation.  
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Although both CTX and CTX-NO, at the concentrations investigated, were unable 
to inhibit glioma cell invasion completely, NO did enhance the anti-invasive properties of 
CTX. This was partially due to decreased MMP-2 and MMP-9 surface expression and 
activity by the NO released from CTX-NO. Invasion of glioma cells involves a variety of 
other MMPs, integrins and chemokines. Accordingly, it is likely that other enzymes are 
also affected by NO treatment. Postovit et al. showed that NO treatment resulted in 
activation of soluble guanylyl cyclase (sGC) and the subsequent activation of protein 
kinase G (PKG), which in turn phoshorylates proteins [279]. This resulted in inhibition of 
tumor cell invasion via the inhibition of urokinase plasminogen activator receptor 
(UPAR) expression [279]. NO has previously been shown to downregulate hypoxia-
inducible factor α (HIF-α), a protein that activates the transcription of numerous proteins 
involved in angiogenesis and tumor invasion [157]. Additionally, NO has been shown to 
impair the function of mitochondria, and Wang et al. speculate that impaired 
mitochondria may reduce the energy supply for cell invasion or alter the expression of 
proteins involved in invasion, leading to decreased tumor cell invasion [157]. Another 
mechanism by which NO has been shown to inhibit tumor invasion is by upregulating 
tissue inhibitor of matrix metalloproteinase 2 (TIMP-2) [266]. Nitric oxide plays a 
complex role in tumor invasion, and although further studies need to be carried out, work 
discussed herein suggests that NO aids CTX in glioma invasion inhibition by decreasing 




CHAPTER 5: CONCLUSIONS AND FUTURE WORK 
 
GBM is the most aggressive and prevalent kind of tumor in the central nervous 
tumor. For a number of years cytotoxic chemotherapeutic drugs have been used to treat a 
variety of tumors, including GBM. However, the non-specific nature of these 
chemotherapeutics necessitates that most anti-cancer drugs be administered at the 
maximum tolerated dose, which in turn leads to a variety of side effects in the patient. 
Therefore, in order to increase the survival of patients suffering from various cancers and 
minimize the toxic side effects of chemotherapy, it is imperative that targeted 
therapeutics be developed. In this thesis, the synthesis and characterization of two 
targeted NO donors, VTW-NO and CTX-NO is presented. Additionally, studies 
investigating the chemosensitizing and invasion inhibiting effects of CTX-NO are 
discussed. 
 
5.1 Results and Implications 
Synthesis and characterization of glioma targeting NO Donors 
NO therapy has long been considered a promising avenue for glioma therapy, but 
the complexity of NO signaling, as well as the difficulty in balancing the potential side 
effects of NO donors, has limited its success in vivo. Therefore, in order to fully harness 
the chemotherapeutic effects of NO while at the same time minimizing its toxic side 
effects, GBM-targeting NO donors were synthesized. Studies presented in Chapter 2, 
using two different glioma-targeting biomolecules, CTX and VTW, demonstrated that 
peptides and proteins can be converted into NO-releasing diazeniumdiolates in a simple 
103 
 
reaction with NO gas. Furthermore, fluorescent and confocal microscopy studies showed 
that the targeting abilities of CTX-NO and VTW-NO were retained after the reaction of 
the biomolecules with NO.  
Additionally, incubation of the NO donors with HB, an extracellular NO-
scavenger, showed minimal attenuation of the cytotoxic effects of the NO donors. This 
suggested that the NO donors are efficiently endocytosed by glioma cells and most of the 
NO is released within the cell. Most importantly, it was demonstrated that targeted NO 
donors can inhibit glioma cell viability without significant harm to human astrocytes and 
brain microvascular endothelium. The work presented in Chapter 2 provides evidence to 
show that targeted NO delivery is an attractive treatment option for GBM, particularly 
because of the method’s minimal toxic effects on normal cells. The techniques used to 
synthesize targeted NO donors, discussed in Chapter 2, can easily be modified to develop 
NO donors that are specific to different tumors.  
 
Effect of targeted NO delivery on the chemosensitivity of glioma cells 
GBM, in addition to being characterized by aggressive and highly invasive 
growth, is among the least therapeutically responsive tumors. The complex nature of 
GBM physiology has shown that for an effective treatment, a multimodal approach must 
be employed for tumor treatment. Hence, it was necessary to study the effect of CTX-NO 
on the chemosensitivity of glioma cells. Viability studies showed that a two hour 
pretreatment with CTX-NO resulted in an enhanced chemosensitivity towards BCNU and 
TMZ in glioma cells, but no sensitizing effects were observed in astrocytes or endothelial 
cells. Further studies showed that NO pretreatment resulted in decreased MGMT 
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expression, suggesting that MGMT played a role in the reduction of chemoresistance in 
glioma cells elicited by NO. A possible mechanism for the NO-mediated reduction in 
MGMT levels is the S-nitrosylation of the cysteine residue in the active site of MGMT, 
which results in decreased enzymatic activity. Additionally, it was found that NO 
pretreatment decreased p53 levels in GBM cells. This is particularly interesting because 
GBM cells often have mutations in the p53 protein which result in diminished ability to 
trigger apoptosis. A decrease in wildtype p53 indicated that NO increased nuclear 
retention of the protein leading to increased apoptosis. 
While all of the precise mechanisms by which NO induces chemosensitivity are 
yet to be elucidated, the work discussed in Chapter 3 demonstrates that targeted NO 
delivery can enhance the chemosensitivity of glioma cells by decreasing MGMT and p53 
levels (Fig. 5.1). This work verifies that targeted NO delivery can be used to sensitize 
cells towards chemotherapeutics and this therapy holds great potential as an adjuvant in 
the multimodal treatment of the numerous tumors that are normally unresponsive to 
chemotherapy. 
 
Figure 5.1. Proposed mechanism by which CTX-NO induces chemosensitivity in glioma cells. 
CTX-NO binds to the MMP-2 complex and is consequently internalized. NO is released in the 
intracellular space inhibiting the effect of DNA repair enzyme, MGMT and triggering the nulear 
localization of wildtype p53. These changes result in the glioma cells being more susceptible to 




Effect of targeted NO delivery on the invasive properties of glioma cells 
The highly invasive nature of GBM has proven to be a major obstacle to the 
successful treatment of GBM. The infiltrative nature of the tumor makes complete tumor 
resection without the loss of neurological function nearly impossible. Therefore, to 
successfully treat GBM, it is imperative to inhibit glioma cell invasion. While CTX has 
well documented anti-invasive properties, the role of NO is debated. In Chapter 4, the 
differences between the effect of CTX and CTX-NO treatments on glioma cell invasion 
and migration were investigated.  
Boyden chamber studies showed that CTX-NO enhanced the ability of CTX to 
inhibit glioma cell invasion through Matrigel. Additionally, it was observed that CTX-NO 
also enhanced the ability of CTX to inhibit glioma cell migration. These studies suggest 
that NO has an inhibitory role in glioma cell invasion and to elucidate the mechanism by 
which this occurs, surface expression and activity of two important ECM degrading 
proteinases, MMP-2 and MMP-9, were quantified after treatment with CTX or CTX-NO. 
As CTX is known to bind to MMP-2, it is not surprising that CTX-NO was able to 
decrease MMP-2 surface expression. An added benefit of CTX-NO was its observed 
ability to decrease MMP-9, which CTX was unable to decrease. The reduction in 
enzymatic activity may be a consequence of reduced MMP expression or a result of NO 
exposure.  
Hence, these studies suggest that even small doses of NO have anti-invasive 
properties, and this is due in part to the inhibitory effects of NO on MMP-2 and MMP-9. 
Invasion of glioma cells involves a variety of other MMPs and chemokines, therefore it is 
probable that other enzymes are also affected by the NO treatment. Though the work 
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discussed herein suggests that NO works synergistically with CTX to attenuate glioma 
cell invasion, it is recognized that tumor physiology is very complex and NO affects 
numerous pathways in the body; hence further studies are needed to validate the use of 
CTX-NO as a GBM therapeutic. Some avenues of further research are discussed in the 
following section. 
 
5.2 Future work and Applications 
Effect of CTX-NO on permeability of BBB 
The BBB barrier is a major hindrance to drug delivery for the treatment of GBM. 
The transcellular tight junctions found in the endothelial cells that make up the BBB 
severely restrict the movement of soluble factors between the endothelial cells and the 
cerebrospinal fluid. While this barrier plays a critical role in preventing bacteria from 
reaching the brain, chemotherapeutics that have a molecular weight of greater than 400-
500 Daltons are unable to passively cross the BBB. It is therefore of great interest to 
investigate the effect of targeted NO on the BBB.  
It is hypothesized that the targeted NO delivery will affect the regions of the BBB 
that are in close proximity to the tumor. It is anticipated that CTX-NO treatment will 
increase the permeability of the BBB and result in greater tumor site accumulation of a 
systemically delivered drug. In order to test this hypothesis, it is suggested that brain 
endothelial and glioma cell co-culture models be used. An in vitro model that can be used 
to study the effects of CTX-NO on the BBB involves the use of collagen-coated Boyden 
chambers. Brain endothelial cells and astrocytes grown to monolayers on the upper and 
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lower sides of the inserts have been shown to be a reproducible model for studying the 
effects of drugs on the properties of the BBB [280-282]. 
 
Effect of CTX-NO on angiogenesis  
 Angiogenesis, the formation of new blood vessels, plays a pivotal role in GBM 
tumor growth, as it provides the tumor cells with oxygen and nutrient supply. NO, at 
certain concentrations, is able to inhibit not only the proliferation of endothelial and 
smooth muscle cells but also endothelial cell migration that ultimately results in an 
inhibition of tumor angiogenesis [126, 283-285]. Conversely, NO has also been 
implicated in promoting tumor angiogenesis [286, 287]. Therefore determining the effect 
of CTX-NO on angiogenesis is necessary before it can be considered as a viable anti-
glioma drug.  
One of the commonly used methods to investigate the effect of biomolecules on 
angiogenesis is the use of tube formation assays [62, 236, 238, 261]. The assay involves 
seeding endothelial cells on Matrigel- or collagen-coated well plates. Cells are then 
treated with the drug of interest and tube formation is visualized at various time points, 
using a microscope. NO has also been shown to affect the expression of VEGF, an 
important mediator of angiogenesis [287]. In addition, NO inhibits platelet aggregation, 
which store angiogenic factors and stimulate angiogenic vessel growth. It would therefore 






In vivo studies  
In vitro studies are widely used to study the effects of novel chemotherapeutics 
since they provide a convenient model to screen drugs for cancer treatment. However, 
this model has severe limitations because it provides an isolated environment in which to 
study the effects of the investigational drug [288]. In vitro tumor cells have access to 20% 
oxygen, a full complement of nutrients, and plenty of space [5]. In contrast, in vivo 
oxygen levels can be lower than 1% and nutrient access is intermittent which often results 
enhanced chemoresistance in GBM cells [5]. Furthermore, it is expected that interactions 
with normal glial cells, neurons, immune cells, and the tumor microenvironment, which 
often has regions of low pH, will affect the kinetics of NO release as well as its efficacy 
as a chemotherapeutic. Therefore, in order to mimic the more complex nature of human 
physiology it is imperative to perform in vivo studies.  
To test the efficacy of CTX-NO as a valid GBM treatment, it is recommended 
that animal studies be performed using intracranial rat glioma models or subcutaneous rat 
models. While the intracranial models mimic the microtumor environment to a greater 
degree and have been used extensively in recent studies [146, 289, 290], the 
subcutaneous models remain a popular choice due to the ease of use and accurate 
knowledge of the location of the tumor [61, 62, 291-295]. Performing animal studies with 
intratumoral injections of CTX-NO will provide a greater insight into the potential role of 
targeted NO as a therapeutic for GBM patients.  
This work has demonstrated the efficacy of CTX-NO as a valuable cytotoxic, 
chemosensitizing and anti-invasion drug. Improving GBM treatment remains a challenge 
and in this thesis a novel approach for the treatment of this tumor is presented. Although 
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NO donors have previously been investigated as potential GBM treatments, this is the 
first study to develop a glioma-targeting NO donor. The material developed herein may 
be easily translated into a novel adjuvant to current cancer therapies. 
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